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1. Summary 
Objective. Wegener’s granulomatosis (WG) is characterized by granulomatous inflammation 
of the respiratory tract and anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated 
systemic vasculitis. The pathognomonic ANCA in WG is typically directed against proteinase 
3 (PR3). Germinal centre-like clusters of lymphocytes were identified in granulomata of WG 
patients suggesting an antigen-driven maturation of B lymphocytes potentially leading to 
ANCA formation. The goal of this study was to develop a system to determine the specificity 
of B cells found in WG granulomata via the generation of fab fragments as antibody 
analogues. These fab fragments have the identical antigen binding site like the B-cell receptor 
from which the DNA was derived.  
Methods. Single B cells were isolated from B-cell clusters within the granuloma of a WG 
patient by laser-assisted microdissection. Their immunoglobulin genes (VH/Vκ, VH/Vλ) were 
characterized by seminested single cell PCR and cloned into a phagemid vector in order to 
produce fab fragments. The fabs were characterized by protein gel electrophoresis and 
western blot. 
Results. The immunoglobulin genes from lymphocyte infiltrates of WG granulomata reveal 
antigen-driven selection. On the basis of two individual couples of mutated VH/Vλ PCR 
products functional fabs were generated that represent the B cell receptors of WG tissue-
derived single B cells. 
Conclusion. This is the first in vitro model to test for specificity of B cell receptors from WG 
granulomata. With respect to ANCA origin in WG this system provides a tool to elucidate the 
structure-function relationship of apparently antigen-driven maturation of B cells within 
Wegener’s granuloma. 
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The results of this study have been presented and published in: 
 
1) J. Voswinkel, A.J. Kerkdijk, A. Mueller, G. Assmann, M. Pfreundschuh, G. Held. A novel 
system to test for specificity of B-cell receptors from tissue of Wegener’s granulomatosis 
patients. Clin Exp Rheumatol 2008; 26 (Suppl. 49): S90-S96. 32 
 
2) Kerkdijk AJ, Held G, Mueller A, Gross WL, Pfreundschuh M, Voswinkel J: Development 
of a System to Test for Specificity of B-cell Receptors found in Granulomatous Lesions of 
Wegeners Granulomatosis patients. 37th annual meeting of the German Society for 
Immunology, Heidelberg. 
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2. Introduction 
2.1 Immunological background information 
 
Secondary lymphoid structures include Peyer’s patches and the mucosa-associated lymphoid 
tissues. Environmental stimuli can promote the development of these secondary lymphoid 
structures from clusters of lymphoid tissue-inducer cells and DCs in the lamina propria, the 
so-called “cryptopatches”5. Tertiary lymphoid structures are ectopic accumulations of 
lymphoid cells found in locations which are non-lymphoid and are very similar to secondary 
lymphoid organs. For instance, specialized high-endothelial venules have been detected5. 
How tertiary lymphoid structures arise is unknown, but it is probable that chronic cytokine 
expression plays a role as tertiary lymphoid structures have been found in diseases like 
Hashimoto’s thyroiditis, rheumatoid arthritis, ulcerative colitis and Sjögren’s syndrome5. In 
these tertiary lymphoid structures immunohistochemical analysis showed the presence of 
germinal centers5. The lymphoid structures which are found in the granuloma-like formations 
of Wegener’s granulomatosis also show a histological pattern consistent with a germinal 
center and can therefore also be considered lymphoid like structures20,33. 
2.2 Characteristics of Wegener’s granulomatosis 
Wegeners granulomatosis is a disease entity with three important clinical characteristics27:  
 
1. Necrotising granulomatous inflammation of the respiratory tract 
2. Pauci-immune Glomerulonephritis 
3. Systemic small-vessel vasculitis 
 
At the Chapel Hill International Consensus Conference in 1992, Wegener’s granulomatosis 
was defined as: 
 
Granulomatous inflammation involving the respiratory tract, and necrotizing vasculitis 
affecting small to medium sized vessels (e.g., capillaries, venules, arterioles, and 
arteries)12 
 
“Classic” Wegener’s granulomatosis takes a biphasic course16. The initial phase is mainly 
characterized by granulomatous inflammation of the upper and lower respiratory tract, but 
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granulomatous manifestations of disease are possible in virtually every organ. After a variable 
amount of time generalization takes place and problems associated with glomerulonephritis 
and systemic vasculitis evolve. Once the disease has generalized, untreated patients show a 
rapidly progressive fatal disease course10, which necessitates immunosuppressive treatment. 
 
As a result of the changing nature of the disease over time, the European Vasculitis study 
Group (EUVAS) has defined the following disease stages, based upon clinicopathological 
considerations. 
 
Table 11: Definition of disease stages by the European Vasculitis Study group (EUVAS) by 
clinico-pathologic criterias. It was agreed that the level of immunosuppression should reflect 
the severity of vasculitis. 
 
Clinical subgroup Constitutional 
symptoms 
ANCA status Threatened vital organ 
functions 
Localized No Negative/positive No 
Early systemic Yes Positive No 
Generalized Yes Positive Yes 
Severe renal Yes Positive Yes 
Refractory Yes Positive/negative Yes 
 
Localized disease refers to the granulomatous manifestations of the disease in various organ 
systems, of which the respiratory tract is most often affected without signs of vasculitis. 
Early systemic WG refers to the disease stage which is characterized by signs of vasculitis 
without renal involvement or vital organ failure. Generalized WG refers to the systemic 
disease with renal involvement. 
 
2.2.1 Clinical characteristics 
 
As mentioned above, WG can be divided into a localized and generalized, systemic form.  
Approx. 42% of patients are diagnosed within 3 months of symptom onset, but a correct 
diagnosis might take years to be established10. Ninety percent of patients first seek medical 
care because of upper or lower airway symptoms10. 
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Below, we will discuss the disease manifestations which can occur in various organ systems 
based upon a number of review articles and large long-term studies of WG patient cohorts 
10,16,25
. 
 
Localized disease 
 
Upper airway manifestations based upon granulomatous inflammation include nasal 
obstruction caused by mucosal swelling, crusting and bloody nasal discharge or epistaxis and 
in advanced disease stages necrosis of the nasal cartilage with subsequent perforation of the 
nasal septum15, a complication which might not become clear initially because of the mucosal 
swelling 1. Another consequence of this necrosis is the saddle-nose deformity, see the figure 
below. Further, paranasal sinus involvement is possible with chronic sinusitis and consequent 
headache, serosanguineous discharge and chronic cough and nasal congestion1. Otitis media, 
mastoiditis and hearing loss might also occur15. At diagnosis, 93% of patients have upper 
respiratory tract symptoms25. 
 
 
 
Figure 1:  
Saddle nose deformity,  
permission for reproduction kindly 
granted by Dr. Stephen Foster 
 
Lower airway manifestations of  WG include subglottic stenosis, which occurs in 10-20% 
of WG patients and occurs in 8% of patients at presentation25. Eighty-five percent of WG 
patients eventually develop lung disease throughout the course of their disease10.  According 
to one study roughly 45% of patients present with pulmonary infiltrates, nodules or both at 
initial presentation. Using CT-scans these percentages are even higher, 50-70% of patients 
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have abnormal chest CT-scans1. Bronchial ulcers as a result of granulomatous inflammation 
might also occur. Symptoms which might arise are cough, hemoptysis and pleuritis10. 
 
Generalized disease 
 
Generalization is the occurrence of  systemic vasculitis. Upon generalization constitutional 
and rheumatic complaints occur: malaise, fever, night sweats, weight loss and polymyalgia, 
arthralgia or arthritis16, these symptoms announce generalization or relapse of disease. 
 
Renal involvement ranges from asymptomatic abnormalities in the urine sediment to the 
pulmonary-renal syndrome. 
 
The pulmonary-renal syndrome is the most serious consequence of the generalized 
vasculitis with rapidly progressive necrotizing glomerulonephritis resulting in renal failure 
and alveolar hemorrhage with very high mortality if untreated16. 
 
2.2.2 Epidemiology of Wegener’s granulomatosis 
 
The prevalence of WG is an estimated 23.7 – 156.5 per million18, the combined annual 
incidence of the ANCA-associated, predominantly small-vessel vascultides Wegener’s 
granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome is 10-20 per million34.  
There seems to be a north-south gradient for the incidence of WG with the highest incidence 
in the Scandinavian countries34, suggesting an environmental factor involved in the 
pathophysiology of WG, see table 2. 
 
Table 2. Incidence of WG in Europe (per million population) 
Norway 10.5 
UK 10.2 
Germany  8.0 
Spain 4.9 
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Population based surveys indicate a mean age of onset which lies between 50 to 66 years18. 
There is some evidence for a slight male predominance in WG, but the evidence is 
inconclusive18.  
 
WG seems to be less prevalent in non-whites; a study from France found a prevalence for WG 
which was half as high in non-Europeans from Africa, Asia and the Caribbean as compared to 
whites18,34. There have been a number of case-control studies which link silica-exposure to 
risk of WG with an odd-ratio of 2.5-518. Another important environmental factor is chronic 
nasal carriage of Staph. aureus, which will be discussed in more detail below. 
 
2.2.3 Anti-neutrophil cytoplasmic antibodies (ANCAs) 
 
There is a subgroup of small-vessel vasculitides which are ANCA-associated: 
 
1. Wegener’s granulomatosis 
2. Microscopic polyangiitis 
3. Churg-Strauss syndrome 
 
Anti-neutrophil cytoplasmic antibodies (ANCAs) probably play a very important role in the 
pathogenesis of Wegener’s granulomatosis. They are IgG antibodies and there are two ways 
to detect the presence of these antibodies. The first way is through indirect immuno-
fluorescence (IIF). Ethanol-fixed neutrophils from healthy donors are incubated with patient 
serum and two distinct staining patterns can be recognized. There is the cytoplasmic staining 
pattern where most of the IgG which is not washed away in the test stains cytoplasmic 
components of the neutrophils. This staining pattern is diagnostic for the presence of cANCAs 
(ANCAs which mainly stain the cytoplasm). Another staining pattern which can be 
recognized is the perinuclear pattern, where staining mainly occurs around the nucleus, 
proving the presence of pANCAs (ANCAs which mainly stain the perinuclear portion of the 
cytoplasm). See figures 2 and 3 for examples. 
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Figure 2:  
cANCA staining pattern by IIF,  
permission for reproduction kindly 
granted by Dr. A.R. Karim 
 
 
Figure 3: 
pANCA staining pattern by IIF,  
permission for reproduction kindly 
granted by Dr. A.R. Karim 
 
Most of the cANCAs and most of the pANCAs are directed against proteinase-3 (PR-3) and 
myeloperoxidase (MPO) respectively2,17. This is the basis for the second diagnostic test used 
in the ANCA-associated small vessel vasculitides: ELISA to check for the presence of anti-
PR3 and anti-MPO antibodies in the serum.  
 
In the following table the sensitivity of indirect immunofluorescence and ELISAs for the three 
ANCA-associated vasculitides is presented: 
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Table 3: Sensitivity of ANCAs for ANCA-associated vasculitides9 
 cANCA 
IIF 
pANCA 
IIF 
cANCA or 
pANCA IIF 
Anti-PR3 
ELISA 
Anti-MPO ELISA 
Wegener’s  64% 21% 85% 66% 24% 
Churg-Strauss-
syndrome 
33% 33% 66% 17-33% 50% 
Microscopic 
polyangiitis 
23% 58% 81% 27% 58% 
 
As can be recognized from this table, WG is mainly associated with cANCAs and MPA is 
mainly associated with pANCAs, although there is some overlap.  
 
The specificity for the ANCAs in disease and healthy controls is shown in the following table. 
Disease controls include patients with other forms of  vasculitis, other glomerulonephritis 
patients, patients with connective tissue diseases and other granulomatous diseases.  
 
Table 4: Specificity of ANCAs determined using IIF and ELISA in patients and healthy 
controls9 
 cANCA 
IIF 
pANCA 
IIF 
cANCA 
or 
pANCA 
IIF 
Anti-PR3 
ELISA 
Anti-MPO 
ELISA 
Disease 
controls 
95% 81% 76% 87% 91% 
Healthy 
controls 
98% 96% 94% 98% 96% 
 
From these data it is clear that neither test gives a satisfying sensitivity or specifity, especially 
the specificity in the group of disease control patients is suboptimal. This problem can be 
solved by combining the IIF cANCA test and the anti-PR3 ELISA. This combination yields a 
56% sensitivity for WG, which is roughly 10% lower than the sensitivities for each separate 
test, but with an almost perfect specificity of 99% in the group of disease-control patients and 
a 100% specificity for the healthy controls9. The sensitivities for the other two diseases in the 
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group of the ANCA-associated vasculitides are much lower and the disease control group 
does not include these other two diseases. Therefore, to delineate WG from these other two 
diseases, clinical and histological data has to be combined. Still, these tests are powerful tools 
in the hands of the clinician, especially to exclude disease.  
 
2.2.4 Proteinase-3 (PR3) 
 
Proteinase-3 is a serine proteinase found in azurophilic granules of neutrophilic granulocytes. 
It has a size of about 29 kDa and preferentially attacks peptide bonds having small aliphatic 
amino acids (alanine, valine, leucine and serine)8,24. The antimicrobial activity is retained 
following denaturation and even peptide fragments still possess antibiotic activities. The 
mechanism of antimicrobial action therefore is not fully understood8. In healthy conditions the 
protein is inhibited by alfa-1-antitrypsin. This inhibition is inhibited by the binding of cANCA 
to PR3 which results in uncontrolled protease activity and might explain part of the 
pathophysiology in the ANCA-associated vasculitides2,8. The cANCAs bind near the active 
site of PR-3 which inhibits proteolytic activity. The sum of these effects is an increase in 
proteolytic activity2.  
 
PR3 remains intracellularly under normal conditions, and is only expressed on the cell-surface 
of neutrophils and endothelial cells in an inflammatory environment. 
 
PR-3 degrades a variety of matrix proteins including fibronectin, laminin, vitronectin and 
collagen type IV24. 
 
Crystal structure analysis has shown that PR-3 forms tetramers8. 
 
Binding of ANCAs to PR3 
 
ANCA bind to PR3 on neutrophils with their F(ab’)2 portion and to neutrophil Fc-gamma 
receptors IIa and IIIb via the Fc portion2,23. ANCA-induced neutrophil activation requires 
both these receptors to be engaged2,27. 
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2.3 Pathogenesis 
2.3.1 Fienberg’s hypothesis 
 
The Fienberg hypothesis states the biphasic nature of  the clinical course of WG on a 
pathophysiological background: WG starts as a granulomatous disease out of which the 
systemic vasculitis develops1. The earliest lesions in the respiratory tract are foci of swollen 
collagen fibers, representing a small nidus of necrosis, out of which the granulomatous lesions 
arise. The strongest argument for this theory is the chronological course of the events in WG: 
first there is the granulomatous lesion, and the systemic vasculitis usually follows after a 
variable span of time. Oppononents of this theory might claim that these early foci of 
fibrinoid necrosis were a consequence of necrotizing capillaritis1. This basically is the 
argument that the vasculitis is the origin out of which the granuloma arises. 
 
Some very important observations have substantiated Fienberg’s theory and an extension of 
this theory forms the basis of this doctoral thesis. There are indications that the granulomatous 
lesions represent ectopic lymphoid tissue which serves as a breeding-ground where the B-
cells which produce PR3-ANCAs arise. The evidence for this hypothesis comes from the 
following observations33: 
 
1. B cell clusters can be found within granulomatous formations from endonasal biopsy 
specimens of WG patients 
2. Analysis of the B cell receptor coding regions showed evidence of a high mutational 
frequency and clonal expansion, which is characteristic of a germinal center, in which 
antigen-selection takes place 
3. Plasma cells, PR3 and neutrophils expressing PR3 were found in the vicinity of the B-
cell clusters 
 
These observations give rise to the possibility that the granulomatous lesion is a lymphoid 
tissue where affinity-maturation takes place on an unknown antigen resulting in B cells with 
PR3 affinity and could present the “missing-link” between localized, granulomatous disease 
and systemic, ANCA-associated  disease. In some patients of this study33 there was a skewing 
of mutations towards negatively charged amino-acids, consistent with a maturation process on 
the positively charged PR3-protein. 
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2.3.2 Evidence for a pathogenic role of ANCAs in WG 
 
A number of studies have appeared during the last 15 years providing evidence for a 
pathogenic role of ANCAs in the pathogenesis of WG. Since the glomerulonephritis which 
causes morbidity in WG is a pauci-immune glomerulonephritis, the damage to the glomerulus 
cannot be explained by deposition of immune complexes. A very important clue to what the 
pathogenesis of WG might be came from a study by Ronald J. Falk6 in 1990. He incubated 
normal human neutrophils with ANCA-positive sera. He made the following discoveries: 
 
1. The release of reactive oxygen species (ROS) from neutrophils was increased after 
incubation with ANCA-sera and with purified ANCA-IgG as compared to normal 
sera.  
2. Superoxide release was noted only when neutrophils were primed with TNF before 
incubation.  
3. Primary granule degranulation was noted after incubation with ANCA IgG, but only 
after priming with TNF.  
4. When neutrophils were primed with TNF flowcytometry analysis showed that MPO 
was expressed at the cell surface. 
 
The latter finding could explain the fact that superoxide release and primary granule 
degranulation only take place after priming with TNF. Priming obviously makes the antigen 
for the ANCAs available at the cell-surface so neutrophils can be activated, whereas in normal 
neutrophils the antigen is not available because it is stored in secretory granules within the 
cell. 
 
This very important study gave a first idea about the pathogenesis of pauci-immune vasculitis, 
in the absence of immunecomplexes in the glomerulus. In this model neutrophil priming takes 
place through an unknown factor, for instance an infection, after which the neutrophils 
degranulate in the presence ANCAs and set free reactive oxygen species which cause 
vasculitis. 
 
 In vivo evidence for a role of ANCAs in the pathogenesis of WG was provided by a pivotal 
study by Xiao et al35. 
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In the Xiao study MPO-knockout mice were immunized with either MPO or BSA and anti-
MPO antibody (MPO-ANCA) titers developed in MPO-immunized mice. Splenocytes from 
both groups of mice were injected into RAG2-/- mice. These mice lack functioning T- and B-
cells. All mice receiving splenocytes developed urinary abnormalities, but only mice who 
received anti-MPO splenocytes developed severe necrotizing and crescentic 
glomerulonephritis as well as segmental or global glomerulal necrosis. None of the mice who 
received anti-BSA or control splenocytes developed glomerular crescents. Furthermore, of the 
16 mice who received the anti-MPO splenocytes one developed necrotizing arteritis in spleen 
and lymph nodes, one necrotizing arteritis in the lungs and five developed hemorrhagic 
pulmonary capillaritis. To ascertain that these effects were really due to the antibodies and not 
because of T-cells which are present in the splenocytes five RAG2-/- and six wild-type mice 
were injected with purified anti-MPO IgG or anti-BSA IgG. All five rag2-/- mice had focal 
necrotizing glomerulonephritis and crescents, none of the three mice which received anti-BSA 
IgG had histologic lesions. The same was true for wild-type mice. Focal pulmonary alveolitis 
was seen in two of the six wildtype mice that received anti-MPO IgG. The glomerulonephritis 
which was induced by the anti-MPO splenocytes and anti-MPO IgG was similar to the pauci-
immune glomerulonephritis seen in humans with small-vessel vasculitis. 
 
The Xiao study was the first in vivo indication that MPO-ANCA might have a causative role 
in the development of the pauci-immune glomerulonephritis seen with the ANCA-associated 
vasculitides. 
 
The role of ANCAs in the pathogenesis of WG can be summarized in the following picture 
which shows neutrophil priming, possibly by an infection leading to release of 
proinflammatory cytokines, upregulation of adhesion molecules on both neutrophils and 
endothelial cells and ANCAs binding to neutrophils with both their Fc-portions and their 
antigen-binding site leading to degranulation which sets free reactive oxygen species which 
causes endothelial damage, which translates to vasculitis. 
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Figure 4: 
Role of ANCAs in pathogenesis of vasculitis in WG13 
 
Association with Staphylococcus Aureus 
 
There is an association between chronic nasal carriage of Staph. aureus and relapse rates in 
WG. In one study30 22 of 33 patients with chronic nasal carriage had a relapse as compared to 
only 1 of 21 persistently negative patients, the relative risk was 7.16 with a confidence 
interval of 1.63 to 31. Treatment with co-trimoxazole leads to a significant reduction in 
respiratory tract and other infections and leads to a significant reduction in the incidence of 
relapse in WG patients who are in remission29. Furthermore, chronic nasal carriage of Staph. 
aureus is three times higher in WG patients as compared to healthy people22. Staph. aureus is 
known for its potent immunostimulatory effect22. This effect mainly comes from its 
exotoxins, which act as superantigens. These superantigens are able to stimulate T cells 
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unspecifically, that is they can bind to MHC class II molecules outside the peptide-binding 
groove and still activate the T-cell22. Staphylococcus Aureus might play an important role in 
the initiation of inflammation in the respiratory tract, after which a granulomatous lesion is 
formed. Also, it might act as an antigen with similarity to PR3 leading to crossreactivity and 
formation of the PR3-ANCA. Interestingly, there are B cell superantigens like SPA and SED, 
present in staph. aureus bacteria, that activate B cells via conserved structures of IgG without 
T-cell help, which could, within the granuloma-like structures of Wegener’s granulomatosis, 
lead to B-cell expansion. Of note, the B-cells which can be stimulated by these superantigens 
are of the VH3-23 immunoglobulin family and this family was also predominantly found in 
our analysis of B-cells derived from granuloma-like formations of Wegener’s patients. 
 
2.4 Hypotheses and goals of this study 
 
Our hypothesis is that formation of the cANCA producing B-cells takes places within the 
granulomatous lesions seen in Wegener’s granulomatosis and that PR3 is the antigen on 
which this affinity maturation takes place. Other possible candidates for the antigen on which 
the apparent affinity maturation takes place are epitopes of Staph. aureus. Staph. aureus 
colonisation of the upper respiratory tract is associated with higher relapse-rates in Wegener’s 
granulomatosis and therefore seems to have a role in pathogenesis. To prove our hypothesis 
we aimed to define the specificity of the B-cell receptors from B-lymphocyte-rich clusters 
within granulomatous lesions. The goal of this study was to devise a system which enables us 
to investigate the specificity of the B-cell receptors found in the afortementioned 
granulomatous lesions, possibly giving new clues to the pathogenesis of Wegener’s 
granulomatosis. To achieve this goal we isolated single B-cells from the aforementioned 
granulomatous lesions and using the DNA isolated from these B-cells set out to produce Fab 
fragments. A Fab fragment is an antibody lacking the Fc-fragment, while preserving the 
highly variable antigen-binding part of the antibody. We modified the Pces1 vector in such a 
way that the separate cloning of DNA coding for variable heavy and light-chain becomes 
possible. Intact Fab fragments based on the isolated B-cells were produced, which can then be 
used as an antibody analogue, for specificity testing. 
  
 18 
2.5 Preliminary work 
 
The material which was the basis for the present study was the result of preliminary work 
performed in the laboratory of Rheumaklinik Bad Bramstedt, Lübeck. In summary, nasal 
biopsy specimens of two WG patients were obtained. If the tissues showed the typical 
granulomatous formations of WG they were immunohistochemically treated with anti-CD20 
to identify B-cells. Individual B-cells from these granulomatous formation which were 
located in the aforementioned germinal-center like structures were isolated using a laser 
technique as described by Fink et al.7 and Küppers et al.14. This is shown in the following 
pictures. 
 
 
Figure 5:  
Laser-assisted capture of a single  
B-cell from a granulomatous lesion 
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Figure 6: 
Laser-assisted capture of a single  
B-cell from a granulomatous lesion 
 
 
Figure 7: 
Laser-assisted capture of a single B-cell from a granulomatous lesion 
 
The result of this laser technique was the isolation of individual B-cells. These individual B-
cells each contain only one copy of the entire genome, including the rearranged VDJ segment 
which codes for the B-cell receptor. Thus, this is a very small quantity of DNA. We 
characterized the VDJ segment of the variable domain of both the light and heavy chain of the 
B-cell receptor, in order to construct Fab-fragments. It is possible to amplify these DNA 
segments by using PCR techniques, as described below. To perform PCR, primers need to be 
constructed which are specific for the different types of V and J segments. However, 
beforehand it is unknown which V and J family is present in the excised B-cell, as the V and J 
segments are available in multiple copies in the genome.  Consecutively two rounds of PCR 
were performed where in the first round a mixture of all primers specific for the different 
“families” of V-segments was used combined with a mixture of primer specific for the 
 20 
different J-segments which are available for the variable domain of the heavy chain and both 
λ- and κ- variety of the light chain. Whatever combination of V(D)J segment exists in the B-
cell, it is amplified by this PCR because all possible VDJ-segment combinations are 
represented by the primers we employed. After this first round of PCR the VDJ segment has 
been amplified but it is still unknown to which “family” the V segment belongs. Therefore, a 
second round of PCR was performed where the DNA resulting from the first round of PCR 
was used to perform a series of PCRs where in each individual PCR only one primer, specific 
for only one family was used. The product of each PCR was run through a gel using 
electrophoresis. If a DNA-product was identified, the specific “clan” to which the V segment 
used in that B-cell belongs, has been determined, as it is equal to the clan for which that 
primer is specific. For instance, there are about 40 different copies of the V segment of the 
heavy chain, which can be grouped, on the basis of sequence-homology into about six 
“families”. Six different primers specific for each family can be used to make six different 
PCRs on DNA of a single B-cell. The differences between the primers are large enough so 
only one primer will bind to the DNA and yield a DNA product on gelelectrophoresesis, 
which is shown in the following picture where six different PCR products resulting from 
PCRs performed with the six different primers are displayed. In this case the variable segment 
of the heavy chain belongs to the VH3-family. 
 
 
Figure 8: 
Second round PCR (see text for explanation of first and second round PCR) 
 
The product in the third lane, shown in the picture above, was excised from the gel and this 
was also done for both the heavy and light chains, yielding two PCR products for each single 
B-cell which was isolated from the granulomatous formations of WG patients. 
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This procedure was done for two B-cells from two different patients. For each cell a light- and 
heavy chain PCR product was isolated from the gel, as described above. The following table 
shows the designations which were given to the B-cells isolated from the two patients (St, and 
Scu), along with the light chain. 
 
Table 5: Names of two B-cells derived from two WG patients and their light-chain subclass 
B-cell Light 
chain 
St140 κ 
Scu68 λ 
 
2.6 Phage display technology 
 
As described in “hypotheses” we wanted to produce a Fab fragment. To achieve this goal we 
used phage display technology. 
 
Introduction 
Phage display is a technique to investigate protein-protein interactions. Recombinant proteins 
are displayed on the surface of phage particles and these phage particles can be used to test 
binding of these recombinant proteins to other proteins. This can be done through “panning 
experiments” where many different phage particles with many different recombinant proteins 
are brought together with a protein which is bound on an ELISA plate so that phage with 
recombinant protein and the target-protein on the plate can engage in interaction and bind to 
eachother. Non-bound phages are washed off, and this selection process, which is called 
“panning”, can be repeated to enrich the percentage of target protein binding phages after 
each round (see figure 9 for the principle). The advantage of phage display is that the phage 
particles display the protein on their surface and within the phage is the DNA which codes for 
this protein. It is thus very easy to find out which recombinant protein bound to the target-
protein by DNA-analysis. A second advantage is that phage can be used to display millions of 
different proteins on their surface in a relatively easy way, thereby allowing the screening of 
millions of different proteins for binding-capability to the target-protein.  
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Figure 9: 
The principle of panning using recombinant proteins displayed on phage19 
 
This technique has been used to investigate host-pathogen interactions, receptor-ligand 
interactions, vaccine development and, very importantly, antibody-antigen interactions.  
Various phage can be used in phage display. The fd filamentous phage is used frequently in 
phage display and is shown in figure 10. Basically, an fd phage is composed of a circular 
single-stranded piece of DNA surrounded by a coat protein and four additional types of 
proteins at both ends of the phage. The DNA codes for these proteins. 
 
Figure 10: 
Filamentous phage fd19 
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Fd phage infect E. coli through protein III (pIII) which adheres to the F pilus of F+ strains of 
E. coli. This causes loss of the F-pilus which prevents superinfection. Recombinant protein 
can be expressed as a fusion protein with pIII through combination of the phage DNA with 
DNA coding for the recombinant protein. The pIII consists of an N-terminal domain, binding 
to the F-pilus and a C-terminal domain which is buried in the particle. Both domains are about 
200 amino acids long. A foreign (recombinant) protein can be fused to the pIII at the N-
terminal end which causes the recombinant protein to be expressed at the tip of the pIII, which 
is necessary of course to engage in a possible interaction with the target protein. 
The life cycle of the fd phage is shown in figure 11. Shortly: the fd phage binds to the F-pilus 
and injects its single-stranded DNA into the E.Coli. Double-stranded DNA is synthesized 
from this single-strand and gene transcription and protein synthesis start from this DNA. 
Eventually new virions are created as the DNA is extruded across the cell membrane where it 
combines with the hull proteins which have accumulated at the cell membrane to form new 
phage which can then re-infect other cells. Note that fd phage is a non-lytic phage, that means 
it does not kill the bacteria it infects which makes it a little bit more difficult to “harvest” 
protein which have been synthesized after infection. These proteins have to be harvested from 
the periplasm where these proteins accumulate, see below. 
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Figure 11: 
Life cycle of filamentous phage19 
 
Methods have been devised which allow the cloning of millions of different recombinant 
proteins into phage DNA. To facilitate this, a so-called phagemid has been constructed. A 
phagemid is a hybrid of phage DNA and a normal plasmid vector. Because the phagemid can 
be handled as a normal plasmid, the standard parallel transformation (see “transformation”) of 
millions of different DNA-coding sequences into this plasmid is possible. Usually a dual 
construction is chosen where the phagemid vector codes for the pIII protein plus recombinant 
protein and an antibiotic resistance gene. This phagemid vector can be transformed (see 
“transformation”) into E.Coli. To produce phage with which to conduct experiments a helper 
phage is used to infect these transformed bacteria. This helper phage contains the full DNA-
code for all the phage proteins and allows phage assembly. This results in phage with both 
wild-type pIII and pIII combined with recombinant protein preserving infectious capability of 
the pIII while at the same time allowing panning experiments to be performed using the pIII 
which displays the protein of interest. Another advantage of having both wild-type pIII and 
fusion protein pIII on the surface is that it allows the selection of recombinant protein with 
high-affinity to the target protein as opposed to mere high avidity. The helper phage also 
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contains an antibiotic resistance gene and in this way only those E.Coli survive which have 
both been infected by helper-phage and carry the phagemid.  
Phagemids can be mass-transformed to create a mixture of phage which present hundreds or 
even millions of different proteins on their surface. This mixture is called a “phage library”. 
Random peptide libraries can be created where phagemids are transformed with randomly 
created oligonucleotide inserts yielding random proteins on the pIII protein. Another 
possibility is the creation of natural peptide libraries where the genomes of selected 
organisms, such as for instance bacteria, are cleaved to the appropriate size and used as inserts 
in the phagemid for a library where only peptides which occur in these bacteria are expressed. 
 
Production of Fabs using the Pces1 vector 
We used the phagemid vector Pces1 which was used in the phage-display method as 
developed by Hoogenboom4 to produce Fab-fragments. We did not use this phage-display 
system for the actual determination of specificity for the Fab fragments thus produced.  
The phagemid vector Pces1 contains an ampicillin resistance gene and the DNA encoding the 
protein III hullprotein (gIII) as shown in figure 12. In front of the gIII region there is a piece 
of DNA which codes for a protein which becomes fused to the protein III. This is the site 
where the recombinant protein of interest has to be cloned into the vector. This site and the 
pIII DNA segment are under the influence of the PlacZ promotor. This promotor is 
suppressed by glucose and IPTG acts as an irreversible inhibitor. This allows regulation of 
expression of the fusion protein. Between the DNA segment coding for the recombinant 
protein and the protein III there is an amber codon. This amber codon stops transcription in 
about 50% of cases, which means that the protein is also produced without attachment to the 
pIII. This allows the Pces1 vector also to be used as a general expression system for the 
recombinant protein, without fusion to the pIII phage protein. We used this possibility to 
produce our Fab fragment. There is also a His-tag at the end of the recombinant protein which 
is an aminoacid sequence which allowing binding of the protein using His-binding beads. 
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Figure 12: 
Schema of Phagemid vector Pces1 
 
For our purpose, the Pces1 vector has been cloned in such a way that following the PlacZ 
promoter there is a ribosomal binding site (RBS) which is where transcription starts, followed 
by the VJ-segment of the light chain with either the  Cκ or Cλ thereafter, followed by a stop 
codon which stops translation and ensures the light chain is produced as a separate protein. 
Thereafter there is another RBS, followed by the DNA coding for the variable and constant 
domain of the heavy chain. The DNA-coding for the constant domain only codes for the CH1 
domain, as this is a Fab-fragment and not a complete antibody. In front of both the light and 
heavy chain there is a “signal sequence”, which causes an aminoacid sequence to be placed 
before both light and heavy chains which makes sure the produced proteins are excreted into 
the periplasm. In the periplasm the signal sequence is cleaved off and correct folding of the 
protein takes place  and also disulfide bridges between heavy and light chain are formed. The 
DNA segment coding for the variable light and heavy chains can be exchanged by cutting the 
DNA with DNA restriction enzymes, see the picture below. In such a way different Fab 
fragments can be produced. See below for a more detailed explanation of the DNA restriction 
sites used. 
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Figure 13: 
Schema of Phagemid vector Pces1 with restriction enzyme recognition sites 
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3. Methods 
 
3.1 Patients 
 
Patient St: 
Patients St. was a 48-year old male patient with an acute and aggressive course of generalised 
WG. About 3 months before the biopsy symptoms started with dyspnoea, recurring headaches 
and a conjunctivitis which was refractory to therapy. After admission to the hospital the 
patient was diagnosed histologically with both an active ulcerative conjunctivitis, and a 
chronic active ulcerative rhinitis. Chest-CT revealed single, partly confluating, 
intrapulmonary round lesions with a serous pneumothorax. ANCA titer was 1:128 (anti-PR3 
36 U/ml). Furthermore, the patient suffered from diabetes insipidus due to a tumor in the 
pituitary gland, which was diagnosed using an MRI scan, consistent with a pituitary gland 
granuloma. Even before biopsy an induction therapy according to Fauci was started with high 
dosed cortisone and cyclophosphamide. In the biopsy of the left lower lobe of the lung the 
diagnosis of WG was confirmed. Here, there was geographic necrosis with histiocytic walls, 
single multinucleated giant cells, microabcesses rich in granulocytes and small arteries with 
transmural lymphoplasmacellular and monocytic inflammatory infiltrates. 
 
Patient Scu: 
Patient Scu was a 64-year old female patient with a protracted course of a localised WG. She 
was ANCA-negative and presented with an aggressive endonasal involvement. Initially she  
was treated with MTX and therafter with cotrimoxazole for a period of 19 years, after which 
the biopsy was taken. In the biopsy of the left and right nasal sinuses there was necrosis, 
inflammatory infiltrates of lymphocytes, plasmacells and granulocytes, as well as epitheloid 
cells and single giant-cells.  
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3.2 Overview of methods 
 
As described above we started to work with the DNA coding for the variable domain of the 
heavy and light chains derived from individual B-cells which were lasered out of 
granulomatous formations of WG patients. This DNA first has to be sequenced to determine 
the DNA sequence. To facilitate sequencing we cloned the heavy- and light-chain DNA-
fragments into the Topo-vector. Then these DNA-sequences had to be compared to a database 
of known DNA segments coding for the variable segments of the heavy and light chain to 
determine if the light chain was either a κ- or λ-chain and also to check if the DNA which was 
isolated was monoclonal. There is always the danger that the lasering technique which is 
intended to capture one cell accidentally captures two or even more cells which makes it 
impossible to determine which light chain belongs to which heavy chain, rendering the 
sample unusable. Another reason to sequence is to check if the DNA is complete and if not, if 
certain pieces of DNA need to be added.  
Thereafter the appropriate primers had to be devised to perform a PCR reaction leading to the 
attachment of the appropriate DNA restriction sites to the B-cell DNA, which is only possible 
if the DNA sequence is known. Thereafter another round of sequencing is necessary to 
determine if the PCR was successful.  
Thereafter the light and heavy chains could be cloned into the Pces1 vector in two steps. 
When both the heavy and light chains are cloned into the Pces1 vector it is possible to 
produce the Fab fragments as will be described in detail below. 
When we had the Fab-fragments we were able to do two things: 
1. Perform integrity testing of the produced Fab fragments using SDS-PAGE and 
Western blotting. 
2. Perform ELISA to test for specificity of the produced Fab fragments. 
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3.3 DNA and DNA-cloning techniques 
 
DNA 
DNA is the molecule which carries the genetic information and it is shown in the following 
picture. 
 
Figure 14: 
Molecular structure of DNA 
 
This figure clearly shows that there is a phosphodiester backbone between 2’desoxyribosyl 
moieties and that this backbone has a polarity. One end has a 5’ phosphate terminus and the 
other end has a 3’ phosphate terminus. Attached to this backbone are the purine and 
pyrimidine bases called adenine (A), thymine (T), cytosine (C) and guanine (G). It is the order 
of these nucleotides which contains the genetic code. Guanine and cytosine on the one hand 
and adenine and thymine on the other hand can engage in a specific hydrogen-bond 
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interaction as shown in the following picture. It should be noted that G-C bonding is stronger 
then A-T bonding. 
 
 
Figure 15: 
Base pairing between T&A and C&G is specific 
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Because base pairing is specific, the nucleotides of two different DNA strands can engage in 
an interaction whereby the two strands lie opposite eachother and run in an anti-parallel 
fashion. The two strands form an anti-parallel helix-like structure. This means that one strand 
runs in the 5’ -> 3’ direction and the other runs in the 3’ -> 5’ direction with the nucleotides in 
the middle, engaging in specific hydrogen-bond interaction, where each C on one strand 
couples with a G on the other strand and each T on one strand couples with an A on the other 
strand as shown in the following picture, which shows the helix formed by the DNA-
molecules.  
 
Figure 16: 
Double-helix structure of two DNA strands. 
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The DNA-sequence of two DNA strands can be represented schematically as follows: 
5’-GACTACTA-3’ 
3’-CTGATGAT-5’ 
 
The upper strand is called the ‘sense’ or ‘coding’ strand because it is used during translation 
to determine the amino-acid sequence of a protein. The other strand is called the anti-sense or 
anti-coding strand. Both strands are complementary to eachother because of the specific 
coupling of the two pairs of nucleotides described above. 
 
Restriction enzymes 
Restriction enzymes are enzymes which cut double-stranded DNA at specific sites. Each 
enzyme recognizes a specific nucleotide sequence and then cuts the DNA in a specific way. 
There are restriction enzymes which make ‘blunt’ ends and there are restriction enzymes 
which make ‘sticky’ ends. An example of a restriction enzyme which makes sticky ends is 
EcoRI.  
The EcoRI restriction enzyme recognizes the GAATTC nucleotide sequence. The nucleotide 
sequence before or after this sequence is irrelevant and is therefore shown as x’s in the 
example below. 
Nucleotide sequence before cutting of DNA with EcoRI 
xxxxxxxxxxxxxxxxxxxxxxGAATTCxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxCTTAAGxxxxxxxxxxxxx 
 
Nucleotide sequence after cutting of DNA with EcoRI 
xxxxxxxxxxxxxxxxxxxxxxG             AATTCxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxCTTAA             Gxxxxxxxxxxxxx 
 
As can be recognized from the illustration above the restriction enzyme has cut the DNA and 
‘sticky’ ends have been created. These ends are called ‘sticky’ because they have a DNA 
‘overhang’, which means at their end they are partly single-stranded. If the sticky ends are 
complementary to eachother they can form one DNA-molecule again if the phosphodiester 
bonds are once again formed. There are also restriction enzymes which create non-sticky-
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ends. That means both ends are not complementary to eachother because the overhangs do not 
match. 
The SmaI restriction enzyme makes ‘blunt’ ends as shown here. 
Nucleotide sequence before cutting of DNA with SmaI 
xxxxxxxxxxxxxxxxxxxxxxCCCGGGxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxGGGCCCxxxxxxxxxxxxx 
 
Nucleotide sequence after cutting of DNA with SmaI 
xxxxxxxxxxxxxxxxxxxxxxCCC      GGGxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxGGG      CCCxxxxxxxxxxxxx 
 
We used restriction enzymes from Fermentas (Burlington, Canada). Each enzyme recognizes 
its restriction enzyme recognition site and each enzyme requires a certain buffer where it 
functions optimally. Fermentas company has three different buffers which are used with their 
enzymes. A typical reaction setup is the following. 
 
Plasmid DNA or linear DNA to be  
digested 4 µl  (which represents for instance 2,5 µg DNA) 
10x Puff (yellow, green, or red) 2 µl      
ApaLI (restriction enzyme) 1 µl 
XhoI (restriction enzyme) 1 µl     
H2O 12 µl      
 -- 
 20 µl 
 
This reaction mix was then incubated at the temperature where these enzymes operate best for 
one hour or overnight. Some enzymes can also be deactivated by heating at a certain 
temperature to avoid overdigestion, which is when the enzymes start to cut the DNA 
randomly when all the restriction enzyme sites have already been digested.  
 
Most enzymes have 10 units/µl. One unit is defined as the amount of enzyme required to 
digest 1 µg of lambda DNA in 1 hour at the appropriate temperature in 50 µl of assay buffer. 
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As a rule of thumb 3-4 units/µg DNA  to be digested can be used to digest over a time period 
of at least 2 hours. In the example above therefore 10 units were used (1 µl = 10 units) 
 
Ligation 
A ligase is an enzyme which joins DNA-molecules with compatible, “sticky”, ends to 
eachother by forming the phosphodiester bonds which are present in the DNA backbone.  
A ligase will join all sites with compatible sticky ends to form a contiguous DNA molecule. 
As long as the ends are sticky, the ligase will link the two ends together. The two ends can be 
from different DNA-molecules or they can be from the same DNA molecule. The latter is the 
case if both ends of a linear DNA molecule have compatible sticky ends, thereby forming a 
circular DNA molecule. In this way it is possible to insert a piece of DNA into a plasmid, 
which is a circular piece of DNA (see below). First, the plasmid is cut with a restriction 
enzyme yielding a linearized DNA with sticky ends. Secondly, the DNA-fragment which has 
to be inserted is also cut with the same restriction enzyme. Therefore the sticky ends of both 
the linearized plasmid and the DNA insert are compatible and ‘annealing’ can take place. This 
means that the nucleotides at the sticky end form the complementary hydrogen bonds. Then 
the ligase forms the phosphodiesterbonds in the backbone, thereby forming one circular DNA 
molecule as shown below. 
 36 
 
Fig 17: 
Insertion of a DNA segment in a plasmid 
 
 
The optimal molar ratio between insert and vector is 3:1. As the insert in most cases is much 
smaller than the vector, the weight of DNA which is to be used can have a very different ratio. 
We used T4 DNA Ligase, which is a bacterial ligation enzyme sold by Roche Diagnostics 
(Risch, Switzerland). This enzyme is provided with a 10x ligation buffer. The following setup 
is typical for ligation of an insert into a vector. 
 
Below is an example of a ligation of a 1200 bp insert into a vector which is about 3600 bp. 
The ideal molar ratio is 3:1. Because the insert is three times smaller than the vector 
equimolarity is achieved when using equal amounts of DNA weight. 
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digested Vector   2 µl    
digested Insert   2 µl    
10x Ligation Buffer   2 µl    
T4 Dna Ligase   0,5 µl 
H2O     13,5 µl 
     --    
     20 µl 
 
Cloning of heavy and light chain DNA into Topo Vector 
 
A plasmid is a circular piece of double-stranded DNA which exists in the bacterial cytoplasm 
and uses the enzymes within this cytoplasm for DNA replication and protein synthesis. The 
plasmids used in DNA recombination technology always contain a number of elements. There 
is the origin of replication, allowing the plasmid to be replicated and to survive as the 
bacterial cell divides. It contains an antibiotic resistance gene allowing selection of those 
bacteria who carry the plasmid within them. It also contains a “multiple cloning site”, which 
is a part of the DNA sequence of the plasmid where multiple restriction enzyme recognition 
sequences are located. This allows cloning of DNA fragments into the vector as described 
under “ligase”. A plasmid can also contain other protein-coding sequences, which gives the 
bacteria which carry the plasmid in their cytoplasm certain additional characteristics, 
depending on the proteins which are synthesised from transcription of the plasmid DNA. 
Because we had to sequence relatively short DNA fragments we chose to clone our DNA into 
a plasmid vector first. This allows complete sequencing of even short DNA fragments, 
without loss. The technical reasons for this are detailed in “sequencing”. The Zero Blunt 
TOPO PCR cloning kit from Invitrogen was acquired to clone the heavy- and light-chain 
fragments into the pCR-Blunt II-TOPO vector which is shown in the following figure. 
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Figure 18: 
Schema of pCR-Blunt II-TOPO vector11, 
Copyright of Invitrogen (Karlsruhe, Germany) 
 
The vector is a circular piece of DNA of 3519 base pairs in total and the multiple-cloning site 
is shown in the figure above. This vector contains both a kanamycin and zeocin antibiotic 
resistance gene. In our experiments we used Kanamycin as a selecting agent. The vector we 
used is special because in the middle of the multiple cloning site there is a site where DNA 
can be cloned into the vector without the use of a restriction enzyme. Therefore, blunt DNA-
segments can be cloned into this vector without the need for compatible sticky ends. 
Therefore this vector can be used for cloning virtually any piece of DNA as long as it has 
blunt ends. The vector comes as a linearized piece of DNA with a protein called “Vaccinia 
virus DNA topoisomerase” covalently bound to each end as shown in the following figure or 
cartoon. 
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Figure 1911: 
Cloning into the TOPO vector, 
copyright of Invitrogen (Karlsruhe, Germany) 
 
As shown in figure 19, a double-stranded piece of DNA with blunt ends can covalently attach 
to the DNA-strand of the linearized plasmid with both its 5’ and 3’ hydroxyl group, releasing 
the topoisomerase leading to the insertion of the DNA fragment into the linearized plasmid, 
once again forming a normal, circular plasmid. 
There is also a Topo Vector available which allows the cloning of DNA fragments with TA-
sticky ends, that is the end of the vector has a T overhang. We used this vector to clone our 
light- and heavy chain DNA fragments because in the two rounds of PCR, as described in 
“preliminary work” an enzyme which makes these TA-overhangs was used. 
The following protocol was used to clone our PCR-products into the vector and is called the 
“TOPO cloning reaction”. 
TOPO cloning reaction, also see “Kit contents, media and solutions” 
PCR Product   2 µl 
Salt Solution   1 µl 
Water    2 µl 
pCR II-Blunt-TOPO  1 µl 
 
This is basically a mix of the DNA insert and the vector with the topoisomerase at its ends in 
a salt solution to facilitate the reaction described above. This mix was incubated for 5 minutes 
at room temperature so the reaction could take place. After this we proceeded with 
“transformation” of the plasmid into DH5-α bacteria for reasons discussed below. 
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Transformation and production of competent DH5-α bacteria. 
 
Transformation is the process whereby DNA is introduced into bacteria. We used the 
“chemical” way of transformation. There is also an “electroporation method” where the DNA 
is transferred across the cell membrane by the application of a high-voltage shock. To 
guarantee a high efficiency of DNA take-up into the bacterial cell, DH5-alfa cells were treated 
using a protocol to make them “competent”, which means they are treated so their cell 
membrane takes up DNA more efficiently.  
We used the following protocol to produce competent DH5-α bacteria: 
DH5-α bacteria are grown overnight at 37 °C on an agar plate with SOC-medium. Ten to 
twelf 2-3 mm large single colonies were picked and used to inoculate 250 mL of SOC-
medium and were incubated shaking at 18-22 °C in a glass 2 liter container until the OD at 
600 nm was about 0.6, which took about 20-24 hours. The container was put on ice for 10 
minutes. Then the cells were transferred to 400 ml Beckman containers and centrifuged at 
3000 rpm at 4 °C for 10 minutes. The supernatant was discarded and resuspended in 130 ml 
of TB solution and incubated on ice for another 10 minutes. After that the bacteria were once 
again centrifuged at 3000 rpm at 4 °C for 10 minutes and again resuspended in 25 ml TB-
solution. Under a light swinging motion 1.9 ml DMSO was added, which means the DMSO-
concentration was 7%. Thereafter the bacteria were incubated another 10 minutes on ice and 
aliquoted into 1.8 ml cryotubes. These tubes were then shock-frozen in liquid nitrogen after 
which the solution containing the bacteria was stored at -80 °C for future use. 
The principle of inducing competency in these cells is based on the high chloride 
concentration in the TB solution. The chloride in this solution enters the cells and causes 
osmotic swelling which stretches the cell membrane. The exact mechanism for induction of 
competency however is unknown. 
After the TOPO cloning reaction the newly formed circular plasmid was transformed into 
competent cells using the following protocol. 
1. The solution which contains the competent DH5-α bacteria stored at -80 °C was 
thawed on ice  
2. For each topo cloning reaction 100 µl of this solution were aliquoted 
3. 4 µl of the topo cloning reaction mix (containing the plasmid) was added to this 100 µl 
4. This mixture was incubated on ice for 30 minutes 
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5. After this, the mixture was heat-shocked for 45 seconds at 42 °C after which the 
solution was once again placed on ice 
6. 400 ml SOC medium was added 
7. This mixture was incubated on a shaker at 37 ° C for one hour 
8. The bacteria were plated on an LB-agar-Kanamycin  plate and incubated overnight at 
37°C. 
 
The bacteria should be treated very carefully throughout, avoiding shocks, as competent 
bacteria are very fragile. Therefore the bacteria are handled on ice. After mixing the TOPO 
cloning reaction mix with the competent bacteria, the DNA will be taken up and the heat-
shock adds further to transformation efficiency. After the heat shock the bacteria will contain 
the plasmid and transcription can take place. In this way the antibiotic resistance will develop. 
The SOC medium is added as nutrient for the cells and the one hour incubation time is the 
time in which the antibiotic resistance develops, after which the bacteria are plated and only 
the bacteria which have been successfully transformed survive. Because the number of 
bacteria is much larger than the number of DNA molecules, each bacterium will contain only 
one plasmid and most bacteria will not take up any plasmid and gain no antibiotic resistance. 
The next day colonies can be picked and can be used to inoculate a LB medium which yields 
a homogeneous population of bacteria within this medium. All these bacteria are derived from 
one bacterium and all these bacteria carry within them the same plasmid with the same DNA 
insert. 
This procedure has a number of advantages. As described above this method yields bacterial 
cultures which are monoclonal. This is an advantage when cloning a PCR product into the 
TOPO vector because after the cloning reaction there is a mixture of plasmids with different 
inserts. That is because the PCR product contains a lot of different DNA fragments: there are 
the primer DNA fragments, and there are various PCR reaction products, the majority of 
which will be the intended reaction product, but there are also a lot of DNA products in the 
mixture which are a result of non-specific binding of the primers to the template DNA 
yielding non-sense DNA. The method of transformation as described above allows the 
isolation of plasmid with only one distinct insert, as opposed to a mixture of plasmids with 
different inserts, as it exists right after the TOPO cloning reaction. The second advantage is 
that in this way large quantities of bacteria carrying the plasmid are produced, as the 
inoculated medium can be of any chosen volume. This allows large quantities of DNA to be  
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isolated carrying the PCR product of interest. Therefore this procedure represents a very 
effective way for the isolation of very pure DNA in large quantities. 
As a sidenote, bacterial competency should always be checked before doing the 
transformation reaction. Therefore 1 µg of DNA has to be used to transform the bacteria using 
the abovementioned protocol. Because 1 µg is a lot of DNA it is wise to dilute the 
transformed cells before plating, for instance 10,000x. Then the number of colonies has to be 
counted. From this the number of colonies per µg DNA used in transformation can be 
calculated for a particular batch of bacteria. The unit of competency is colony forming 
units/µg DNA.  
To isolate the plasmids from the monoclonal bacteria which are present in the overnight-
culture we use the TENS-protocol. 
 
Preparation of DNA in “mini”-quantities using the TENS protocol 
This is a protocol which can be used to prepare plasmid DNA from bacterial cultures, yielding 
DNA quantities with a maximum of about 20 µg. 
1. 1.5 ml of the bacterial culture is centrifuged full-speed for 30 seconds 
2. Supernatant is discarded 
3. Pellet is resuspended in 100 µl buffer S1 + RNase  
4. 300 µl TENS-buffer is added 
5. 150 µl 3M NaAc (pH 5.2) is added 
6. The suspension is shaken 
7. Centrifugation full-speed for 10-20 minutes 
8. Supernatant is transferred to new tube 
9. 1 ml -20°C 100% alcohol is added, vortex 
10. Mixture is centrifuged full-speed for 10-20 minutes 
11. Supernatant is discarded 
12. Pellet is resuspended in 1 ml 70% alcohol 
13. Mixture is centrifuged full-speed for 10-20 minutes 
14. Supernatant is discarded 
15. Pellet is allowed to dry 
16. Pellet is resuspended in 25-50 µl of water 
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Usually this will yield a DNA concentration of about 100-250 µg/µl when using a high-copy 
plasmid such as the TOPO vector. 
 
The DNA which has been obtained in this way must thereafter be cleaned of RNA and other 
bacterial debris, see “DNA and Gel Band Purification”. 
 
So, after cloning each light- and heavy chain PCR product into the TOPO vector we 
transformed the plasmid into DH5-α bacteria and plated the bacteria on LB-agar-Kanamycin 
plates and picked colonies. For each transformation we picked 10 colonies and sent these to a 
commercial laboratory for sequencing. 
 
DNA Gel Electrophoresis 
It is possible to separate a mixture of DNA molecules based on their size with an agarose gel 
electrophoresis. The DNA is mixed on the gel and an electrical field is applied which causes 
the DNA molecules to move through the gel. Larger molecules will move slower then small 
ones. After some time the separation of the DNA molecules can be visualised by illumination 
with a UV light. The DNA will be visualized because ethidiumbromide is present in the gel. 
The combination of ethidiumbromide and DNA is fluorescent under UV-illumination. The 
illumination pattern can then be compared to a “ladder” which is a DNA mixture with DNA 
molecules of known size.  
 
First, the agarose gel was prepared according to the following recipe for a 1.5 % agarose gel 
 
1. Prepare TAE from a stock solution of 50x TAE 
2. Add 1.5 gram of agarose to 100 ml of this stock-solution 
3. Cook in a microwave until the agarose is dissolved 
4. Let the solution cool off, and add water which has evaporated by cooking 
5. Add ethidiumbromid to a final concentration of 0,5 µg/ml 
6. Poor this solution into a container which forms the gel including the holes for loading 
the DNA and remove air bubbles 
7. Let it cool off until the gel is solid 
 
After the gel is ready the DNA is loaded into the gel using the loading holes, but before 
loading the DNA is mixed with loading dye. The gel is also loaded with a ‘ladder’ to compare 
DNA size. The “ladder” is a mixture of DNA fragments with known size so that it can be used 
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as a reference to determine the size of an unknown DNA fragment in a gel. We used the 
“Generuler” from Fermentas. Then a voltage of about 100 V is applied for about 30-45 
minutes. An example illustrating the principle of a DNA ladder is shown in Figure 20.  
 
 
Figure 20: 
DNA ladder used in gel electroforesis 
 
After the gel electrophoresis has been run, the mixture of DNA was separated and the 
appropriate bands of DNA can be cut out of the gel using a scalpel. Thereafter the DNA has to 
be prepared from the gel. 
 
DNA and Gel Band Purification 
For purifying DNA from solution or an agarose gel we used the “GFX PCR DNA and Gel 
Band Purification Kit” from Amersham Biosciences (Amersham, UK). This kit can be used to 
purify DNA from a solution which also contains protein (for instance cellular debris from 
TENS-preparation), salts, primers (after a PCR), restriction fragments (after restriction 
enzyme digestion of DNA)  or to isolate DNA from a TAE gel. 
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The principle is as follows: the gel or solution is incubated with an agent which denatures 
protein, dissolves agarose and promotes binding of DNA to a glass fiber matrix. The fiber 
matrix is then washed with a washing solution and thereafter the DNA is eluted from the 
matrix using water. All these steps involve centrifugation between steps. DNA fragments 
which are captured are from 100 bp to 48 kbp.  
 
Polymerase chain reaction 
The polymerase chain reaction is a method with which a target sequence of DNA can be 
multiplied. Normal DNA replication, which occurs when the cell divides and two identical 
copies of the double-stranded DNA molecule have to be generated is performed by an enzyme 
called DNA polymerase. DNA replication takes place when the two strands dissociate from 
eachother under the influence of certain enzymes, thereafter each strand is used as a template 
to create the opposing strand again, thereby generating identical copies. As the DNA 
polymerase moves along the DNA molecule two new molecules are created. This principle is 
shown in the following two pictures. Note that DNA replication naturally takes place in a 
discontinous fashion on one of the two strands which are being replicated, since the DNA 
polymerase can only operate in the 5’ to 3’ direction. DNA replication always needs a certain 
“primer”, this is a short stretch of RNA which is complementary to part of the DNA strand. 
The place where the primer binds to the DNA template is where the DNA-polymerase can 
start its work. There are many places where these RNA primers bind and therefore many 
stretches where a piece of DNA has been replicated, such a stretch is called an Okazaki-
fragment, see figure 22. 
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Figure 21: 
Illustration of DNA-replication 
 
Figure 22: 
Okazaki fragment, 
e=primer, f=Okazaki-fragment 
 
The DNA polymerase molecule can be used in vitro to multiply DNA molecules too. Let’s 
assume we have a piece of DNA which is a couple of thousand basepairs long. Within this 
DNA molecule there is a certain segment which is important to us and we want this segment 
to be multiplied. We can then make a certain reaction mix containing this DNA molecule, the 
DNA polymerase, a mixture of nucleotides (G,C,T,A) and two primers in water with 
appropriate pH and salt concentrations. The primers are necessary as starting point for DNA 
replication as we saw above. In vitro, however, the primer is not a piece of RNA, but a short 
piece of DNA. The first primer is constructed in such a way that it is complementary to the 
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sense strand at the start of the DNA segment which is to be amplified. The second primer is 
complementary to the anti-sensestrand at the end of the DNA segment which is to be 
amplified. By putting this mixture through an automated series of temperature changes it is 
possible to repeat DNA replication of the DNA segment between the two primers.  
 
The reaction mixture is put through the following temperature steps. First, the temperature is 
raised to 95°C to cause the two strands of the DNA molecule to dissociate (“denaturation”), 
allowing the primer to attach to the single DNA strands at a temperature which is dependent 
upon the length and nucleotide composition of the primers, and is generally about 50-70°C. 
This process is called “annealing”. Thereafter, DNA replication can take place at a 
temperature of 72°C, which means that the DNA polymerase makes a double-stranded 
molecule again by complementing each nucleotide on the template DNA strand using the 
nucleotides present in the reaction mixture. This temperature is of course much higher than 
the temperature at which normal DNA replication takes place. This can be explained by the 
fact that the DNA-polymerase which is used in vitro is a bacterial DNA polymerase which 
can withstand much higher temperatures than human DNA polymerase. This is necessary 
because denaturation temperatures are very high and would inactivate the human DNA 
polymerase. This cycle can be repeated many times. Each time only the DNA segment 
between the primers is replicated and in such a way the DNA is replicated 109 times after 30 
cycles. The principle is illustrated in the following picture. 
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Figure 23: 
Illustration of the principle of the polymerase chain reaction 
 
As indicated above, the annealing temperature to be chosen depends upon the length of the 
primer and the nucleotide content thereof. As a rule of thumb the following formula can be 
used to calculate annealing temperature (Tm). 
  
Tm = 2°C (A+T) + 4°C (G+C) 
 
Where A,T,G,C represent the number of these nucleotides in the primer.  
 
When designing primers it is important to have a G or C at the end of the primer because the 
bonding between the G and C nucleotides is stronger then the bonding between T and A, in 
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this way the chance for proper annealing is increased. When the nucleotide sequence of a 
certain DNA molecule is known, usually only the sense strand is shown. For instance: 
 
5’- AGGCTTGGTGCCTCCGCCGAACACCTCGTGCTGCTATCATAAGACTGACAG 
TAGTAGTCAGCCTCGTCCTCAGTCTTCAGTCCAGAGA-3’ 
 
If we want to amplify the underlined DNA segment we should make two primers as follows. 
The first primer, which designates the start of the DNA segment to be amplified, is called the 
5’ primer. This primer attaches the anti-sense strand. Therefore, it has to be complementary to 
the anti-sense strand and therefore the 5’ primer is equal to the start of the DNA segment to be 
amplified: 
 
5’- Primer 
5’-CACCTCGTGCTGCTA-3’ 
 
The primer which designates the end of the DNA segment to be amplified is called the 3’ 
primer. This primer attaches to the sense strand. If we take the end of the DNA segment to be 
amplified from the sequence above and draw in the anti-sense strand it would look like this: 
 
5’TCAGCCTCGTCCT-3’ 
3’AGTCGGAGCAGGA-5’ 
 
From this picture it is clear that if we are to make a primer which attaches to the sense strand 
we should take the reverse complement of the sense-strand which is: 
 
3’- Primer 
5’AGGACGAGGCTGA-3’ 
 
Primers are always synthesized in the 5’ -> 3’ direction.  
 
We ordered our primers from MWG Biotech (Ebersberg, Germany). 
 
Using the formula which was shown above, we can calculate the annealing temperature for 
our primers. When we use longer primers the annealing temperature will be higher. The 
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advantage of using longer primers is that the specificity increases. With increasing primer 
length the chance of  primer-binding to DNA segments, which are similar to the DNA 
segment to be amplified, decreases. In this way PCR can be used to amplify a segment of 
DNA which is present in a mixture of DNA molecules or to amplify one small part of the 
whole genome, all because primer binding is highly specific. In the single cells which were 
isolated from granulomatous lesions of WG patients, the heavy- and light-chain coding 
segments are only 350 basepairs long and the rest of the entire humane genome is also 
present. After the PCR reaction, however, most of the DNA in the reaction mix is the DNA 
which codes for the heavy- or light chains of the antibody because this DNA segment has 
been amplified tremendously. 
 
Another very important application of PCR is the possibility to add nucleotides to the DNA 
segment which is to be amplified. We did this by adding the nucleotides in front of the primer 
sequence we designed. We used this to add the restriction enzyme recognition sites in front of 
the DNA segments we work with, so we could use these sites to make “sticky” ends, so we 
could clone the DNA-segment into for instance the Pces1 vector. Annealing temperature was 
calculated only on the basis of the formula given above. 
If we wanted to add the GAATTC (EcoRI) restriction enzyme recognition sequence at both 
ends of the DNA segment in the example we presented above we would change the sequence 
of our 5’ and 3’ in the following way: 
 
5’- Primer 
5’-GAATTC CACCTCGTGCTGCTA-3’ 
 
3’- Primer 
5’GAATTC AGGACGAGGCTGA-3’ 
 
This would result in a DNA fragment after the PCR reaction with the following sequence: 
 
5’- GAATTC CACCTCGTGCTGCTATCATAAGACTGACAGTAGTAGTCAGCCTCGTC 
CT GAATTC-3’ 
 
The primer will attach, even though during the first cycle the first few nucleotides (GAATTC) 
of the primer have no match in the DNA template. This is no problem as long as the number 
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of added nucleotides is not too big. After annealing the DNA replication will start at the 
beginning of the primer, thereby incorporating the added nucleotides into the DNA molecule. 
In subsequent rounds, the primer will attach 100% correctly to the DNA-template since the 
added nucleotides will now be available in the DNA template. 
 
It is also possible to use a mixture of primers, if large numbers of nucleotides have to be 
added. More about this in “results”. 
 
We used Proofstart ™ DNA polymerase from Qiagen® for our PCRs and set up the following 
reaction mixture. 
 
         Final concentration  
10x Proofstart PCR Buffer  5 µl  1x 
dNTP Mix (10 mM of each)  1,5 µl  300 µM of each 
Primer 1  0,5 µl  1 µM 
Primer 2  0,5 µl  1 µM 
Proofstart DNA Polymerase  1 µl  =2,5 units 
Distilled water  40,5 µl 
Template DNA  1 µl   
      -- 
      50 µl 
 
The following PCR program is used: 
Step 1  Activation:   5 min 95 Grad 
Step 2 Denaturation:   1 min 94 Grad 
Step 3 Annealing:  1 min 50-72 Grad 
Step 3 Extension  1 min 72 Grad 
Step 4 Repeat   goto 2 30 times 
Step 6 72 Grad 7 Minuten   
Step 7 Hold at 4°C forever 
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Sequencing 
Sequencing is a method to determine the nucleotide sequence of DNA. We sent our DNA-
samples to a laboratory which used the Sanger method of sequencing. In this method four  
PCR reactions are set up using a single primer which binds to the DNA-segment of the DNA 
molecule where sequencing should start is included. Within the reaction mix there are the four 
nucleotides which are used for DNA synthesis as in all PCR reactions. In each of the four 
reactions one type of nucleotide is also present as a dideoxynucleotide. When this nucleotide 
is used for DNA-synthesis it leads to termination, because no further nucleotides can be 
attached to the dideoxnucleotide. Because the concentration of the dideoxynucleotide is only 
0.02 % of the concentration of the normal nucleotides the termination events, for statistical 
reasons, generally take place within the first 200-500 basepairs after the start of DNA 
synthesis, which is at the site where the primer binds. Therefore, after the PCR there is a 
mixture of DNA-fragments with a length of up to 500 basepairs. Either the primer or one of 
the normal nucleotides can be marked with a fluorescent or radioactive substance. This makes 
it possible to determine the length of the different DNA fragments by applying it to an 
electrophoresis gel which separates the DNA fragments based on size. This enables 
determination of the nucleotide sequence of the original template. When a termination event 
takes place it means that at that position a certain dideoxynucleotide was built in which 
identifies the complementary nucleotide on the template-DNA strand. For each of the four 
reactions a number of DNA fragment sizes will be found. For each reaction, the sizes of these 
DNA fragments indicate where this nucleotide can be found in the DNA sequence, relative to 
the the primer-annealing site. In this way the identity of each nucleotide of the template DNA 
strand can be identified by combining the results of the four reactions. This is shown in the 
following figure. 
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Figure 24: 
Principle of sequencing according to Sanger 
 
When using the TOPO vector, we used the M13 Reverse primer, which attaches to the M13 
reverse priming site as a starting point for sequencing. With this primer, the insert in the 
TOPO vector is always sequenced. 
 
3.4 Cloning of variable chain coding DNA segments into the Pces1 
vector 
 
Using the techniques described above it is possible to prepare the variable chain segments in 
such a way that they have the restriction enzyme recognition sequences forming sticky ends. 
The appropriate restriction enzyme recognition sequences are also available in the Pces1 
vector and after a restriction enzyme digest the DNA insert will have compatible sticky ends 
so it can be ligated into the Pces1 vector. This is depicted in the following picture. 
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Figure 25: 
Schematic picture of the cloning reaction 
 
The picture above shows schematically that a variable chain coding DNA segment was put 
through a PCR to add the restriction enzyme recognition sites to its ends. After a digest of this 
insert the DNA has sticky ends. The vector is also digested, which frees a “dummy” piece of 
DNA as a restriction fragment. The vector and the dummy insert can be separated from 
eachother on an agarose electrophoresis gel and the digested Pces1-vector at this point also 
has sticky ends and can then be cut out of the gel to be incubated with the insert in a ligation 
reaction. After that transformation and DNA preparation can take place.  
 
For a better understanding of the exact cloning reactions we performed here, again, is the 
figure showing the Pces1 vector. 
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Figure 26: 
Pces1 vector, S = signal sequence, Cκ = constant domain of K light-chain,  
CH1 = constant domain of heavy chain 
 
The exact DNA sequence of the Pces1 restrictiction enzyme recognition sequences is shown 
below. The light chain was inserted into the vector using the ApaLI restriction enzyme at the 
5’ end and the XhoI restriction enzyme at 3’ end. For the heavy chain the SfiI and BsteII 
restriction enzymes were used to clone the insert into the vector. 
 
ApaLI 
5'-G^T G C A C-3' 
3'-C A C G T^G-5' 
 
XhoI 
5'-C^T C G A G-3' 
3'-G A G C T^C-5'  
 
SfiI 
5'-G G C C N N N N^N G G C C-3' 
3'-C C G G N^N N N N C C G G-5' 
 
BsteII 
5'-G^G T N A C C-3' 
3'-C C A N T G^G-5'  
 
These restriction enzyme sites can be found in the vector at appropriate locations as indicated 
below. 
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Part of Pces1 vector DNA sequence 
-- 
Signal sequence 
GTGAAAAAATTATTATTCGCAATTCCTTTAGTTGTTCCTTTCTATTCTCACA 
 
ApaLI 
GTGCAC AA  
 
Variable chain (κ) 
GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAG
TCACCATCACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAGCCTGGTATCA
GCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAA
AGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCA
CCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCAACAGGCTAA
CAGTTTCCCTCCAAGCACCTTCGGCCAAGGGACA 
XhoI 
CTCGAG 
ATT AAA CGA  
 
Constant domain κ 
ACTGTGGCTGCACCATCT 
-- 
 
From this sequence it can be seen that the restriction enzyme recognition site lies at the end of 
the signal sequence and that the first codon of the variable chain kappa coding sequence starts 
with GAC. Everything after the ApaLI restriction enzyme recognition site is part of the insert 
and when designing the primer for the PCR with which we attach these sites to the insert it is 
very important to stay “in frame”. That is, DNA is read and translated into an amino acid 
three nucleotides at a time, which is called the “frame”. If one nucleotide is lacking the DNA 
will be read in a different frame. Therefore, the AA nucleotides have been added right after 
the ApaLI site , they cause the variable chain to be read “in frame”. The XhoI site is located 
such that the first three nucleotides form one codon and the second three form another codon. 
Right after the XhoI site there are three more amino acids and thereafter the constant domain 
 57 
of the light chain begins. The M13 Reverse priming site is located in the vector before the 
signal sequence and allows sequencing of the vector at the site of the light chain. 
 
For those cells which have a λ light chain we mutated a Pces1 vector which has the lambda 
constant domain instead of the kappa constant domain. We started out with a Pces1 vector 
with the lambda constant domain in it instead of the kappa domain, but unfortunately it lacked 
a restriction enzyme recognition site at the end of the variable domain. As shown here: 
 
     ------------------------><-----CDR3--- 
361       TGAGGATGAGGCTGATTATTATTGCTGGTCATTTGCAGGCTCCTATTATGTCTTCGGGAC 
103         E  D  E  A  D  Y  Y  C  W  S  F  A  G  S  Y  Y  V  F  G  T  
 
     ------------------------>------constant lamda IGLC1*02------ 
421       AGGGACCGACGTCACCGTCCTCGGTCAGCCCAAGGCCAACCCCACTGTCACTCTGTTCCC 
123         G  T  D  V  T  V  L  G  Q  P  K  A  N  P  T  V  T  L  F  P 
 
Therefore, we mutated the vector at the CTCGGT site to yield a CTCGAG, which is the XhoI 
site. For mutation technique, see below. 
 
The ligation of the heavy chain is different. The SfiI site is in the signal sequence and quite 
large, followed by two other codons which belong to the signal sequence. Therefore, to clone 
the insert into the vector a lot of nucleotides need to be added to the insert using PCR. 
 
-- 
Signal sequence 
ATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGC 
 
SfiI 
GGCCCAGCCGGCC ATG GCC  
 
Variable domain of the heavy chain 
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGACACCCTG
TCCCTCACCTGCGCTGTCTCTGGTGACTCCCTCGGTAGTTACTACTGGACCTGGAT
CCGACAGCCCCCCGGGAAGGGACTGGAATGGGTGGGTTATATCTATTACAGTGG
GAGCACCAATTATAACCCTTCCCTCAAGAGTCAAGCCGTCATATCAATCGACACA
ACCAACAACCGGTTCTCCCTGAACCTCAGCTCTGTGACCGCTGGAGACACGGCCG
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TGTATTATTGTGTGAGAGGAAACGGCGCGCTCCTATCCTGGGGCCAAGGAACCCT
GGT 
 
BsteII 
GGTCACC 
 
GTCTCAAGC 
 
Constant domain of the heavy chain 
GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCT
CTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTCCCCGAACCGGG
AACGGTTTATTTACA 
-- 
 
For all of our cloning we used so called “midi”-preparations. As described under “Preparation 
of DNA in “mini”-quantities using the TENS protocol” it is possible to grow cultures of 
bacteria and then isolate plasmid DNA from these bacteria. In the aforementioned method we 
used only 5 ml of culture to prepare DNA which yields a “mini” quantitity of DNA. During 
ligation of an insert into a vector it is necessary to have a certain optimal molar ratio between 
these two reactants in the ligation mix. Therefore mini preparations are not suited for ligation 
reactions using the Pces1 vector. This is for a number of  reasons. First, DNA quantities are 
very low in a mini preparation because little culture is used. Furthermore, the Pces1 vector is 
a “low-copy” plasmid, which means that DNA yield is lower because the plasmid does not 
replicate so fast in the cytoplasm of bacteria, which further decreases DNA yield. Because the 
DNA quantities are so low it is hardly possible to measure the DNA quantity which makes it 
more difficult to reach an optimal molar ratio of insert to vector.  
 
Therefore we prepared “midi”-preparations. Midi preparations are DNA preparations where 
about 50 ml of culture is used to prepare DNA and it usually yields a total of 20-100 µg of 
DNA, compared to a maximum of 20 µg for the mini preparations. 
 
We used the “Plasmid DNA Purification” kit from Machery-Nagel (Düren, Germany), to 
isolate the plasmid DNA from the bacteria in culture. This kit uses a procedure similar to the 
TENS-method, where bacteria are lysed, freeing the plasmid DNA. This kit also contains 
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columns to which the DNA binds and after various washing and elutions steps a pure, salt- 
and protein free DNA solution results. 
 
Midi DNA Preparation 
 
We used the following protocol for Midi preparations: 
 
1. Prepare an overnight culture with the bacterium containing the plasmid of interest 
2. Centrifuge for 15 minutes at 4°C at 6000 g 
3. Resuspend the pellet in 8 ml buffer S1 
4. Add 8 ml buffer S2 and mix gently by inverting tube 6-8 times 
5. Add 8 ml pre-cooled (4°C) buffer S3 mix by inverting 6-8 times and incubate on ice 
for 5 minutes 
6. Equilibrate a Nucleobond™ column with buffer N2, 2.5 ml 
7. After passing the lysate from step 5 through a filter, load the lysate on the column and 
allow the column to empty by gravity flow 
8. Wash the column with 12 ml buffer N3 
9. Elute the plasmid DNA with 5 ml buffer N5 
10. Add 3.5 ml room-temperature isopropanol to precipitate the eluted plasmid DNA and 
centrifuge at 15000g for 30 minutes at 4°C 
11. Discard supernatant and add room-temperature 70% ethanol and again centrifuge 
12. Remove ethanol and allow pellet to dry 
13. Resuspend pellet in water of an appropriate volume 
 
We used this protocol to prepare DNA for the Pces1 vector. The heavy and light chain inserts 
were cloned into TOPO again, after which cultures were prepared. From these cultures MIDI 
preparations were made using the protocol above. These MIDI preparations were then 
digested and ligated as described above, which resulted in the inserts being cloned into the 
Pces1 vector at appropriate locations. 
 
DNA mutation 
We used the quikChange™ Site-directed mutagenesis kit from Stratagene for DNA mutation 
of the Pces1 vector.  
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The principle is as follows. First primers are constructed which incorporate the mutation. 
Using these primers, a PCR is run with a DNA polymerase from the kit which causes the 
newly synthesised strand to have staggered nicks. The newly synthesised strand therefore is 
different than the template strand. This allows the template strand to be digested by Dpn I, an 
enzyme, leaving the newly synthesised strand with the mutations in them available for 
transformation into competent bacterial cells where double stranded DNA is again formed.  
 
This is shown in the following picture. 
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Figure 27: 
DNA mutation 
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We constructed two primers which anneal to opposite strands of the vector and which contain 
the desired mutation, CTCGGT to CTCGAG in our case. The primers were constructed so 
that they were between 25 and 45 bases long with a Tm above 78°C.  
 
Mutprim5 CGTCACCGTCCTC GAG CAGCCCAAGGCC (84°C) 
mutprim3 GGCCTTGGGCTG  CTC GAGGACGGTGACG (84°C) 
 
Thereafter we ran a PCR using the provided PfuTurbo DNA polymerase using this protocol: 
 
10x Reaction buffer  5 
Pces1 Vector   2,5 (25 ng) 
Mutprim5   1,5 (125 ng= 15 pmol) 
Mutprim3   1,4 (125 ng= 14 pmol) 
dNTP Mix   1 
H2O    38,6 
    -- 
    50 
 
PfuTurbo DNA polymer 1  
 
We used the following cycling parameters: 
Step 1  Activation:   0.5 min 95 Grad 
Step 2 Denaturation:   0.5 min 95 Grad 
Step 3 Annealing:  1 min 55 Grad 
Step 3 Extension  3.5 min 68 Grad 
Step 4 Repeat   goto 2 18 times 
Step 6 72 Grad 7 Minuten   
Step 7 Hold at 4°C forever 
 
We then did the DpnI digestion and transformed into E.Coli TG1 competent cells, picked 
colonies, grew cultures, isolated DNA and sent this DNA for sequencing to check if the 
mutation was successful.  
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3.5 Production of Fabs using the pCes1 vector 
 
As described in chapter 2.6 “Phage display technology” and chapter 3.2 “Overview of 
methods” soluble antibody fragments were produced by phagemid containing bacteria in low 
glucose medium to which IPTG has been added. These antibody fragments are directed to the 
periplasm because of the signal sequence as described above. The following protocol was 
used for preparation of these periplasmic antibody fragments (Fabs). 
 
1. A 50 ml culture of 2TY-AG is inoculated with the bacterium which contains the 
phagemid of interest and grown overnight at 30°C while shaking 
2. 7.5 ml of this overnight culture is inoculated in 750 ml fresh 2TY containing 100 
µg/ml ampicillin and 0.1% glucose and grown at 37°C while shaking at 180 rpm 
3. At OD600 of 0.8 - 0.9 add  1mM IPTG and continue to grow at 30°C for 4 hours while 
shaking at 180 rpm 
4. Centrifuge cells down in 500 ml Beckman containers using no more then 400 ml 
capacity at a time for 15 minutes at 4000 rpm 
5. Discard supernatant and freeze the cells at -20 overnight 
 
The freezing step has shown to give a higher protein yield. 
 
6. Lysing of pellet: thawed pellet is lysed with TES (pH 8.0) and the following 
proteaseinhibitors from Sigma corporation: 
• PHSF (Phenyl Methyl Sulfyl Fluorid) 2 mM 
• Pepstatin 2 mM 
• Leupeptin 10 mM 
• Benzamidin 2 mM 
• Chymostatin 2.5 µg/ml 
 
7.  Dialyse overnight to remove EDTA from TES Solution against PBS pH 8.0 
 
Thereafter Immobilised Metal Affinity Chromatography (IMAC) was used to isolate the Fabs 
from the solution of lysed pellet using the HIS-tag, which is present in the Fabs. The HIS-tag 
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binds to the affinity column because the column is coated with NiSo4, which binds the HIS-
tag.  
 
8. First, the column was equilibrated with 50 ml PBS 
9. Then the column was loaded by filtration across the column of 10 ml 100 mM NiSo4 
10. The column was washed with 30 ml PBS 
11. The pellet lysate was then filtered across the column at 4 ml/min with a peristaltic 
pump 
12. The column was washed with PBS 
13. Then the column was washed with continuously increasing imidazol concentration (0-
150 mM in 20 steps of 5 ml), this is the elution step.  
 
The Fabs were eluted at an imidazol concentration of about 70 mM. 
 
14. The Fab-fraction was dialysed against PBS 
15. Measuring of protein concentration at 280 nM and control of the Fab-fraction in a 
Coomassiegel was performed 
 
3.6 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) of 
Proteins  
 
Once Fab Fragments had been produced we used SDS-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE), as described by Sambrook26, to investigate these proteins and prove they were 
intact.  The SDS-PAGE method allows separation of proteins on the basis of molecular 
weight using a gel in an electrical field. By using a reducing agent, which breaks disulfide 
bridges, it is possible to further analyse the subunits of a certain protein. In our case this was 
useful because the heavy and light chain of a Fab fragment are held together by a disulfide 
bridge. 
 
The principle is as follows. First, the proteins which are to be investigated, Fab fragments in 
our case, are denatured through incubation with SDS. This causes denaturation through 
breakage of  hydrogenbridges removing secondary and tertiary structures rendering the 
protein in its most simple, rod-like,  polypeptide structure. The denatured polypeptides bind 
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SDS and thus become negatively charged allowing separation in an electrical field.  The SDS 
molecule consists of a tail of 12 carbon atoms attached to a hydrophilic sulphate group, giving 
the molecule amphiphilic properties which causes it to act as a detergent.  
 
Figure 28: 
Sodium dodecyl sulfate, C12H25SO4Na 
 
Approximately 1.4 gram of SDS is bound per gram of polypeptide. This causes the charges of 
the polypeptide to become negligible in comparison to the negative charge of the coating 
SDS. Effectively, because of denaturation and coating with SDS the proteins are rendered into 
uniformly negatively charged rod-like structures ideally suited for separation on a gel on the 
basis of size only using an electrical field. The polypeptides are separated in a polyacrylamide 
gel consisting of a mixture of bicrylamide and acrylamide in a ratio of 1:29 which yields an 
optimal separation based on molecular weight. The effective range of separation depends on 
the concentration of polycrylamide in the separating gel. SDS does not break disulfide 
bridges, to break disulfide bridges a reducing agent is required.  
 
Practically, for our experiments, the SDS-PAGE of proteins was conducted as follows. 
For descriptions of buffers used see “Kit contents, media and solutions” at the end of this 
chapter. First, we prepared a 12% polycrylamide gel. Then the gel was poured between two 
glass plates separated by about a millimetre, which hold the gel. The gel is left to polymerize 
for 30 minutes. After 30 minutes the top of the gel was washed with deionized water. 
Thereafter the stacking gel was loaded on top of the polyacrylamid gel, which serves as a 
holding gel for the proteins which are to be separated. Immediately after loading the stacking 
gel, before polymerization occurs, a comb was applied into the stacking gel to create the slots 
into which the proteins to be separated are loaded. The stacking gel was allowed to 
polymerize. 
 
During this time our Fab Fragments were prepared for electrophoresis using two different 
procedures. We prepared a solution with Fab Fragments in a concentration of 100 µg/ml in 
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PBS and incubated with SDS gel-loading buffer for denaturation, whose principle is described 
above. We also prepared our samples under reducing conditions which means that in addition 
to incubation with SDS gel-loading buffer we also cooked the samples at 95° C followed by 
incubation with the β-mercaptoethanol reducing agent for 5 minutes. 
 
After polymerization is complete the wells created by the comb were washed with deionized 
water. The wells were loaded with the samples containing the denatured and reduced proteins. 
Therafter the eletrophoresis was performed by applying an electrical field across the gel with 
a voltage of 180 V applied over a period of one hour.  
 
After this the polyacrylamid gel containing the protein of interest was fixed and stained using 
a mixture of 0.25 g Coomassie Brilliant Blue in 90 ml Methanol:H20 (1:1) and 10 ml of 
glacial acetic acid. The gel was incubated with this staining and fixing solution for 4 hours at 
room temperature. Thereafter the gel was immersed in the Methanol/H2O/acetic acid solution 
for a number of hours until an adequate destaining of the gel with appearance of proteinbands 
was attained. The gel obtained through this method was photographed. 
 
Thereafter the gels were used for Western blotting as described below. 
 
3.7 Western Blotting 
 
Using the polyacrylamid gel obtained as described above we performed a Western blot to 
further prove the integrity of the Fab fragments we produced. Western Blotting is a technique 
in which the proteins which have been separated by SDS-PAGE are transferred to a 
nitrocellulose or polyvinylidene fluoride (PVDF) membrane to be incubated with antibodies 
that recognize certain polypeptide sequences (antigens). The last antibody in the antibody 
cascade is coupled to an enzyme which allows staining when incubated with an appropriate 
substrate.  
The proteins in the polycrylamide gel are transferred to the membrane by placing the two 
media next to eachother in an electrical field sandwiched between two sheets of Whatman 
3MM paper soaked in a transfer buffer which consists of Tris, glycine, SDS and methanol.  
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The transfer of the proteins from the gel takes about two hours and the successful completion 
of this procedure can be checked by staining the proteins on the membrane using Ponceau S, 
which does not interfere with further immunological probing because it is easily washed away 
in subsequent steps. The membrane was incubated with a working solution of Ponceau S, 
thereafter the membrane was washed with deionized water to make the bands visible. 
Thereafter the filter was washed with PBS to remove the Ponceau from the membrane after 
which further immunological probing can take place. In addition to the method of transfer 
above we also used the “semi-dry” method which is basically the same but differs in that only 
the Whatman papers are soaked with transfer buffer, the eletrophoresis using the semi-dry 
method took 30 minutes at 21 V. 
 
We used a PVDF membrane and it was incubated with 10% milk powder at 4° C overnight, to 
block unspecific binding of antibody to the membrane. We then incubated with the primary 
and secondary antibody, whereby the second antibody is coupled to a peroxidase which is 
responsible for the staining of the nitrocellulose membrane in the presence of a substrate. 
 
We used two pairs of primary and secondary antibodies. The first pair which consists of 
mouse anti-Penta-His IgG (Qiagen, Hilden, Germany) followed by goat anti-mouse IgG-
HRP-conjugate (Biorad, Hercules, CA, USA) as secondary antibody, used in a concentration 
of 1:2000 and 1:3000 respectively. This first pair of antibodies reacts against the series of 
histamin peptides in the Fab fragment heavy chain and is therefore, in effect, an anti heavy-
chain cascade. The second pair of antibodies we used consisted of rabbit anti-human-lambda 
IgG (Dako, Glostrup, Denmark) and goat anti-rabbit IgG-HRP-conjugate (Biorad, Hercules, 
CA, USA), used both in a concentration of 1:3000. This second pair of antibodies is, in effect, 
an anti light-chain cascade.  
 
3.8 Enzyme-Linked ImmunoSorbent Assay (ELISA) for Fab testing 
against PR3 
 
The principle of ELISA is as follows. First, a plastic plate with multiple wells, with one well 
for each probe or test to be performed, is coated with a certain target-antigen. The plate is 
made up of material to which proteins readily bind. After overnight coating with the antigen, 
the antigen is fixed to the plate and the coating solution is washed off. Thereafter, the plate is 
incubated with a serum or a solution containing an antibody (either a full antibody, a Fab or 
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even a Fab-expressing phage-particle). This is called the primary antibody. When the primary 
antibody specifically binds the target-antigen it will not be washed off in the subsequent 
wash-steps. Unbound antibody is washed off and the plate thereafter is coated with an 
enzyme-linked antibody against the primary antibody. After more washing the plate is 
incubated with the substrate for the enzyme and the intensity of coloring after a certain 
timeperiod of incubation is related to the amount of primary antibody which bound the target-
antigen. This is therefore a measure for the strength of binding of the primary antibody to the 
target-antigen. Aspecific binding is prevented by “blocking” with a solution of milk powder. 
 
We used NUNC Maxisorb™  96-well plates.  
 
We use this technique to test our Fabs for binding against PR3. 
 
We used the following protocol for ELISA: 
 
1. Coat plates for 2 hours with target-protein with a protein concentration of 2 µg/ml at 
room temperature 
2. Wash 3 times with PBS 
3. Incubate each well with 100 µl Fabs in 1% BSA (bovine serum albumin) in PBS  
4. Incubate for 1 hour 
5. Wash 3 times with PBS-Tween 0.05% 
6. Wash 3 times with PBS 
7. Add 100 µl of the primary antibody in 1% BSA  
8. Incubate for 1 hour 
9. Wash 3 times with PBS-Tween 0.1% 
10. Wash 3 times with PBS 
11. Add 100 µl of peroxidase coupled secondary antibody 1:2000 
12. Incubate for 1 hour 
13. Wash three times with PBS-Tween 0.1%, wash 3 times with PBS  
14. Add 100 µl TMB solution per Well and incubate for 10 minutes 
15. Add 50 µl Stopsolution per Well 
16. Measure OD450 
 
 69 
As a primary antibody we used the Immunostep™ (Salamanca, Spain), Mouse monoclonal 
antibody to human lambda 0,1 mg/ml in diluted 1:500. As a secondary antibody we used 
DAKO™ (Glostrup, Denmark), polyclonal rabbit anti-mouse immunoglobulins. This 
secondary antibody was coupled to HRP: horse radish peroxidase. This secondary antibody 
was diluted 1:2000. The stop solution consisted of 1M H2SO4. 
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3.9 Kit contents, Media and solutions 
 
Contents of the Zero Blunt TOPO PCR cloning kit 
pCR-Blunt II-TOPO     10 ng/µl plasmid DNA in: 
       50% glycerol 
       50 mM Tris-HCL, pH 7.4 (at 25° C) 
       1 mM EDTA 
       2 mM DTT 
       0.1% Triton X-100 
       100 µg/ml BSA 
       30 µM bromophenol blue 
 
Salt Solution      1.2 M NaCl 
       0.06 M MgCl2 
 
Contents of the Plasmid DNA purification kit by Machery-Nagel 
Buffer S1      50 mM Tris-HCl 
       10 mM EDTA 
       100 µg/ml RNase A, pH 8.0 
 
Buffer S2      200 mM NaOH, 1% SDS 
 
Buffer S3      2.8 M KAc, pH 5.1 
 
Buffer N2  100 mM Tris, 15% ethanol, 900 mM KCl, 
0,15% Triton X-100, adjusted to pH 6.3 
with H3PO4 
 
Buffer N3  100 mM Tris, 15% ethanol, 1.15 M KCl, 
adjusted to pH 6.3 with H3PO4 
 
Buffer N5  100 mM Tris, 15% ethanol, 1 M KCl, 
adjusted to pH 8.5 with H3PO4 
Nucleobond™ columns 
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Solutions used for making competent cells 
TB-solution (CaCl2-solution)  10 mM PIPES (C8H18N2O6S2) (3.021 g/l) 
  55 mM MnCl2 (MnCl2 4 H2O 10.885 g/l) 
  15 mM CaCl2 (CaCl2 2H2O 2.205 g/l) 
  250 mM KCl (18.637 g/l) 
  Mix and adjust pH to 6.7 with KOH 
  Sterilization by filtration across a 0.45 µm 
filter 
 
SOC Medium  2% bactotryptone 
  0.5% Yeast extract 
  10 mM NaCl 
  2.5 mM MgCl2 
 10 mM MgSO4 
  
20 mM Glucose 
 
Solutions used in the TENS-method 
TENS-Buffer Solution with:  
1% Tris 1M 
  1% 10 M NaOH 
  5% SDS 10% 
 In water 
 
NaAc 3M pH 5.2  Dissolve 408.1 g of NaAc·3H2O in 800 ml 
H2O. Adjust pH to 5.2 with glacial acetic 
acid. Adjust volume to 1 liter, autoclave 
 
Solutions used in SDS-PAGE 
12% Polyacrylamide gel (20 ml) 6.6  ml  H2O  
 8 .0  ml 30% Acrylamide mix  
 5.0  ml  1.5 M Tris (pH 8.8) 
 0.2  ml 10% SDS 
 0.2     ml  10% Ammonium persulfate 
  0.008  ml TEMED  
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Acrylamide mix  29% acrylamide and 1% 
methylenebisacrylamide in deionized H2O 
 
TEMED N,N,N´,N´-tetramethylethylenediamine 
 (polymerization agent) 
 
5% Stacking Gel (10 ml) H2O 6.8 ml 
 30% Acrylamide mix 1.7 ml 
1.0 M Tris (pH 6.8) 1.25 ml 
10% SDS 0.1 ml 
 10% Ammonium persulfate 0.1 ml 
 TEMED 0.01 ml 
 
1x SDS gel-loading Buffer 50 mM Tris·Cl (pH 6.8) 
  100 mM dithiothreitol 
  2% SDS  
 0.1% bromophenol blue 
  10% Glycerol 
Media used for Western blotting 
Transfer Buffer 39 mM glycine 
  48 mM Tris base 
  0.037% SDS 
 20% methanol 
  To prepare 1 liter of transfer buffer (pH 
8.3), mix 2.9 g of glycine, 5.8 g of Tris 
base, 0.37 g of SDS and 200 ml of 
Methanol 
 
Stock solution of Ponceau S Ponceau S 2 g 
  Trichloracetic acid 30 g 
  Sulfosalicylic acid 30 g 
 H2O to 100 ml 
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Working solution of Ponceau S  1:10 dilution of Stock solution using 
deionized water 
 
Media and solutions 
LB-medium (with Kanamycin)  1% Bactotryptone 
  0.5% Yeast extract 
  1.0% NaCl 
 pH 7.0 
 autoclave 
 (Add 50 µg/ml Kanamycin) 
 
LB-Agar plates with Kanamycin  LB-medium 
  Add agar 15 g/L 
 Autoclave 
 Add 50 µg/ml Kanamycin 
 Pour into plates with diameter of 10 cm 
 Store at 4°C. 
 
Tris-acetate 50x (TAE)  242 g Tris base 
  57.1 ml glacial acetic acid (CH3COOH) 
 100 ml 0.5 M EDTA (pH 8.0) 
 
TE-Buffer pH 7.4 10 mM Tris·Cl (pH 7.4) 
  1 mM EDTA (pH 80) 
 
Tris 1M 121.1 g Tris Base in 800 ml H2O 
 Adjust pH by adding HCl 
  pH 7.4 70 ml 
 pH 7.5 60 ml 
  pH 8.0 42 ml 
 
SDS 10%   100 g SDS in 900 ml H2O. Heat to 68°C 
to aid in dissolution. Adjust pH to 7.0 with 
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a few drops of 10M NaOH solution, adjust 
volume to 1 liter. Autoclave. 
 
PBS       8.75 g NaCl / liter water (750 mmol / liter) 
1.42 g Na2HPO4 / liter water (40 
mmol/liter) 
0.22 g KH2PO4 / liter water (7.8 mmol 
/liter) 
pH should be approximately 7.4-7.6 
 
PEG/NaCl       20% Polyethylene glycol 6000 (PEG) 
       2.5 M NaCl 
       Autoclave 
 
2xTY broth      16 g bacto-tryptone / liter water 
       10 g Yeast extract / liter water 
         5 g NaCl / liter water 
 
2xTY-AG  2xTY broth, containing 100 µg/ml 
ampicillin and 2 % glucose 
 
2xTY-AG plates  2xTY broth, containing 2% glucose, 100 
µg/ml ampicillin and 15 g agar 
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4. Results 
 
4.1 Cloning of DNA coding for the variable heavy and light chain 
domains of antibodies into the Pces1 vector 
 
Table 6: Designations of two B-cells derived from two WG patients and their light-chain 
subclass 
B-cell Light 
chain 
St140 Κ 
Scu68 Λ 
 
 
Each light and heavy chain was cloned into the TOPO vector, the vector was transformed into 
DH5-α bacteria and plated out onto LB/Kanamycin plates. From each product ten colonies 
were picked and sequenced. This was done to check for monoclonality of the product, since it 
is possible that despite careful handling more than one cell is lasered out of the tissue section. 
If the product is not monoclonal, multiple insert will be found, and consecutively not all of the 
10 sequences will be identical. The cells that were used for further investigations were 
monoclonal. 
 
The sequences were analyzed using the IMGT immunoglobulin database. The results of these 
analyses yielded the families to which the particular heavy and light chain belonged to and for 
the light chain it allowed determination of κ- or λ-type. 
 
The results are shown in appendix I. The most important result which is to be noted is that 
most of the heavy-chain coding DNA sequences had to be extended to be used directly for 
cloning into the Pces1 vector. 
 
An example is shown below, it is the sequence of st140. 
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It can be seen that the sequence bears the greatest resemblance to the 4-59 family of DNA-
segment coding for the variable heavy chain of the antibody. The first 18 codons bridging the 
insertion site of the vector’s are missing. For our purposes this is not so important since the 
antibody specificity is determined by the complementary determining regions which is located 
3’ of the variable domain coding DNA.  
 
St140 VH 
 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
st140vh                        ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
L10088 IGHV4-59*01             cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
M29812 IGHV4-59*02             cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
X56360 IGHV4-59*07             cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
M95114 IGHV4-59*03             cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
X87091 IGHV4-59*08             ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
st140vh                        ... ... ..c ctg tcc ctc acc tgc gct gtc tct ggt gac tcc ctc  
L10088 IGHV4-59*01             tcg gag ac- --- --- --- --- --- a-- --- --- --- -g- --- a--  
M29812 IGHV4-59*02             tcg gag ac- --- --- --- --- --- a-- --- --- --- -g- --- g--  
X56360 IGHV4-59*07             tcg gac ac- --- --- --- --- --- a-- --- --- --- -g- --- a--  
M95114 IGHV4-59*03             tcg gag ac- --- --- --- --- --- a-- --- --- --- -g- --- a--  
X87091 IGHV4-59*08             ... ... ... ... --- --- --- --- a-- --- --- --- -g- --- a--  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
st140vh                        ggt agt tac tac ... ... ... ... tgt acc tgg atc cga cag ccc  
L10088 IGHV4-59*01             a-- --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
M29812 IGHV4-59*02             a-- --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
X56360 IGHV4-59*07             a-- --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
M95114 IGHV4-59*03             a-- --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
X87091 IGHV4-59*08             a-n --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
 
As described in “material and methods” we need the complete DNA segment which codes for 
the variable domain of the heavy and light chain to clone into the Pces1 vector to be able to 
produce fabs. For the light chain, the restriction enzyme recognition site is situated at the 
beginning of the DNA coding for the variable chain and for the heavy chain the recognition 
site is situated in the signal sequence some codons 5’ of the DNA coding for the variable 
chain. Both the missing codons and the restriction enzyme recognition site needed to be added 
to the variable domain coding DNA segments. 
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For each DNA segment where codons were missing we used the germline sequence to fill it 
up. In the example above, the St140Vh is most similar to the V4-59 family. Thus the 
particular variable heavy segment bears the highest similarity to the V4-59 family in its non-
recombinant form, and additional mutations are acquired by affinity maturation. This 
germline sequence is shown in the IMGT analysis above. The addition of germline 
homologue gene segments to extend the framework region up to the insertion sequence that fit 
to the vector ligation should not change the affinity of the Fab or antibody produced since the 
complementarity-determining regions are not affected. 
 
In the example above the missing 18 codons were added. 5’ from these codons, a part of the 
signal sequence containing the SfiI restriction enzyme recognition site also was added, 
representing another 19 nucleotides. This is illustrated here. 
  
Signal sequence 
ATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGC 
 
SfiI 
GGCCCAGCCGGCC ATG GCC  
 
Variable domain of the heavy chain 
CAGGTGCAGCTGCAGG etc. etc. etc.  
 
For the heavy chain a total of about 20-24 codons were added, depending on how many 
codons were missing. These codons were added using PCR with “overhanging” primers, as 
was described in “materials and methods”. Twenty-four codons are 72 nucleotides to be 
added at once. The primer itself will exceed this length because it also has to anneal to the 
DNA. This represents a problem since the maximum length of primers which can be easily 
produced in commercial laboratories is 50 basepairs. Consecutively, it is not possible to add 
all of the missing nucleotides to our DNA inserts at once. We therefore chose to do multiple 
rounds of PCR, adding seven codons in each round. This requires different primers for each 
round. The first primer anneals to the DNA present in the insert, the second primer anneals to 
the codons which have been added to the insert in the first round of PCR by the first primer 
and adds more codons to which the primer in the third round attaches etc. The primers thus 
have an overlap, otherwise annealing could not take place. 
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This is illustrated in the following picture. 
 
 
Figure 30:  
Addition of germline DNA and restriction enzyme recognition sites, with overlapping primers 
 
For each of the DNA segments listed in Appendix I primers were devised and they are shown 
here. The 3’ primer is never divided into multiple primers because at the end of the DNA 
sequences there were no missing codons and therefore this primer was used in each round of 
PCR using the 5’ primers. The “theoretical primer” is the primer sequence if we were able to 
add all the required nucleotides in one step. Parentheses () are used to indicate where the 
division is located between nucleotides in the primer which anneal and which nucleotides are 
added. The nucleotides to the left of the parenthesis are added in that particular round. Six G’s 
were entered to protect the DNA segment from random nuclease activity which could lead to 
nucleotide loss. Annealing temperature is shown at the end of each primer. 
 
We purposely chose the restriction enzyme recognition sites in such a way that as much of the 
original DNA sequence was spared so as not to alter the binding properties of the 
immunoglobulin. The results of these considerations are shown below. 
 
St140 vh 
Theoretical primer: 
ggg ggg GCG GCC CAG CCG GCC ATG GCC (end of signal sequence) CAG GTG CAG 
CTG CAG GAG TCG GGC CCA GGA CTG GTG AAG CCT TCG GAC AC()C CTG TCC CTC ACC 
TGC GCT GTC (74 Grad) 
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Divided into: 
5’-first 
CTG GTG AAG CCT TCG GAC AC ()C CTG TCC CTC ACC TGC GCT GTC (72°C) 
 
5’-second 
CTG CAG GAG TCG GGC CCA GGA ()CTG GTG AAG CCT TCG GAC AC C C (72°C) 
 
5’-third 
CCG GCC ATG GCC CAG GTG CAG ()CTG CAG GAG TCG GGC CCA GG (70°C) 
 
5’-fourth 
ggg ggg GCG GCC CAG()CCG GCC ATG GCC CAG GTG CA (70°C) 
 
3’-primer 
GGG GGG ()GGTGACCACCAGGGTTCCTTGGCCCCAGG 
 
St140vk 
5’-primer 
GTG CAC AA GAC ATC CAG ATG ACC ()CAG TCT CCA TCT TCC GTG TCT GC (72°C) 
 
3’-primer 
CTC GAG T () GTCCCTTGGCCGAAGGTGCTTG (72°C) 
 
Scu68vh 
Theoretical 5’-primer 
GGCCCAGCCGGCCATGGCC CAG GTG CAG CTG CAG GAG TCG GGC CCA GGA CTG GTG AAG CCT 
TCG GAG () ACC CTG TCC CTC ACC TGC GCT G  
 
5’-first 
GGA CTG GTG AAG CCT TCG GAG () ACC CTG TCC CTC ACC TGC GCT G (74°C) 
 
5’-second 
CAG CTG CAG GAG TCG GGC CCA () GGA CTG GTG AAG CCT TCG GAG  AC (74°C) 
 
5’-third 
CAG CCG GCC ATG GCC CAG GTG () CAG CTG CAG GAG TCG GGC CCA (72°C) 
 
5’-fourth 
GGG GGG GGCC ()CAG CCG GCC ATG GCC CAG GTG (74°C) 
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3’-primer 
GGG GGG () GGTGACCCCTGTGACCAGGGGTCCTTGGCCC (72°C) 
 
Scu68vl 
5` 
GGG GGG GTGCAC () CCT TCT GAG CTG ACT CAG GAC CC (72°C) 
 
3’ 
GGG GGG CTC GAG () GACGGTCAGCTTGGTGCCTCCG (72°C) 
 
As a rather novel and so far not yet used method we did not perform the PCRs separately, but 
we mixed the primers together in one PCR. The theory behind this is that as soon as the first 
primer has bound to the target DNA sequence and some cycles have been performed the 
nucleotides which are supposed to be added by the first primer are actually added, creating the 
target DNA molecule to which the second primer can attach which leads to addition of more 
nucleotides to which the third primer can bind. Of course, the chance of unspecific primer 
binding and primers binding to eachother increases because in our experiments a maximum of 
5 different primers were present in the PCR mix (four 5’ primer and the 3’ primer). 
 
To investigate the results of each of these mixed-primer PCRs the PCR products were cloned 
into the TOPO vector and transformed into bacteria for sequencing of selected clones. The 
results of this mixing of primers was very different for each PCR which was tried. Two out of 
three PCRs were successful in that all the primers had bound appropriately leading to an intact 
PCR product. In one of three PCR reactions the fourth primer had not bound. For scu68VH 
none of ten PCR products contained the right sequence, which forced us to run the PCRs in 
consecutive rounds.  
 
As a result of these efforts we had the complete DNA sequence of the light and heavy chain 
coding DNA-segments. This is shown below: 
 
St140 VH 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
St140VH                        cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
X56360 IGHV4-59*07             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
L10088 IGHV4-59*01             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
M29812 IGHV4-59*02             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
M95114 IGHV4-59*03             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
M95117 IGHV4-59*04             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
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                               ------------------------------------------> ________________ 
                                               20                  25                  30   
St140VH                        tcg gac acc ctg tcc ctc acc tgc gct gtc tct ggt gac tcc ctc  
X56360 IGHV4-59*07             --- --- --- --- --- --- --- --- a-- --- --- --- -g- --- a--  
L10088 IGHV4-59*01             --- --g --- --- --- --- --- --- a-- --- --- --- -g- --- a--  
M29812 IGHV4-59*02             --- --g --- --- --- --- --- --- a-- --- --- --- -g- --- g--  
M95114 IGHV4-59*03             --- --g --- --- --- --- --- --- a-- --- --- --- -g- --- a--  
M95117 IGHV4-59*04             --- --g --- --- --- --- --- --- a-- --- --- --- -g- --- a--  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
St140VH                        ggt agt tac tac ... ... ... ... tgg acc tgg atc cga cag ccc  
X56360 IGHV4-59*07             a-- --- --- --- ... ... ... ... --- -g- --- --- --g --- ---  
L10088 IGHV4-59*01             a-- --- --- --- ... ... ... ... --- -g- --- --- --g --- ---  
M29812 IGHV4-59*02             a-- --- --- --- ... ... ... ... --- -g- --- --- --g --- ---  
M95114 IGHV4-59*03             a-- --- --- --- ... ... ... ... --- -g- --- --- --g --- ---  
M95117 IGHV4-59*04             a-- --- --- --- ... ... ... ... --- -g- --- --- --g --- ---  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
St140VH                        ccc ggg aag gga ctg gaa tgg gtg ggt tat atc tat tac agt ggg  
X56360 IGHV4-59*07             --a --- --- --- --- --g --- a-t --g --- --- --- --- --- ---  
L10088 IGHV4-59*01             --a --- --- --- --- --g --- a-t --g --- --- --- --- --- ---  
M29812 IGHV4-59*02             --a --- --- --- --- --g --- a-t --g --- --- --- --- --- ---  
M95114 IGHV4-59*03             --a --- --- --- --- --g --- a-t --g --- --- --- --- --- ---  
M95117 IGHV4-59*04             --a --- --- --- --- --g --- a-t --g --- --- --- --t --- ---  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
St140VH                        agc acc ... ... ... aat tat aac cct tcc ctc aag ... agt caa  
X56360 IGHV4-59*07             --- --- ... ... ... --c --c --- --c --- --- --- ... --- -g-  
L10088 IGHV4-59*01             --- --- ... ... ... --c --c --- --c --- --- --- ... --- -g-  
M29812 IGHV4-59*02             --- --- ... ... ... --c --c --- --c --- --- --- ... --- -g-  
M95114 IGHV4-59*03             --- --- ... ... ... --c --c --- --c --- --- --- ... --- -g-  
M95117 IGHV4-59*04             --- --- ... ... ... t-c --c --- --g --- --- --- ... --- -g-  
 
                               -------------------------------  FR3 - IMGT  --------------- 
                                               80                  85                  90   
St140VH                        gcc gtc ata tca atc gac aca acc aac aac cgg ttc tcc ctg aac  
X56360 IGHV4-59*07             -t- ac- --- --- g-a --- --g t-- --g --- -a- --- --- --- --g  
L10088 IGHV4-59*01             -t- ac- --- --- g-a --- --g t-- --g --- -a- --- --- --- --g  
M29812 IGHV4-59*02             -t- ac- --- --- g-a --- --g t-- --g --- -a- --- --- --- --g  
M95114 IGHV4-59*03             -t- ac- --- --- g-a --- --g t-- --g --- -aa --- --- --- --g  
M95117 IGHV4-59*04             -t- ac- --g --- g-a --- --g t-- --g --- -a- --- --- --- --g  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
St140VH                        ctc agc tct gtg acc gct gga gac acg gcc gtg tat tat tgt gtg  
X56360 IGHV4-59*07             --g --- --- --- --- --- -cg --- --- --- --- --- --c --- -c-  
L10088 IGHV4-59*01             --g --- --- --- --- --- -cg --- --- --- --- --- --c --- -c-  
M29812 IGHV4-59*02             --g --- --- --- --- --- -cg --- --- --- --- --- --c --- -c-  
 82 
M95114 IGHV4-59*03             --g --- --- --- --- --- -cg --- --- --- --- --- --c --- -c- 
M95117 IGHV4-59*04             --g --- --- --- --- --c -c- --- --- --t --- --- --c --- -c- 
 
                               _______  CDR3 -  IMGT _________ 
                                
St140VH                        aga gga aac ggc gcg ctc cta tcc tgg ggc caa gga acc ctg gtg  
X56360 IGHV4-59*07             --- 
L10088 IGHV4-59*01             --- -a 
M29812 IGHV4-59*02             --- -a 
M95114 IGHV4-59*03              
M95117 IGHV4-59*04              
 
                                
                                
St140VH                        gtc acc 
X56360 IGHV4-59*07              
L10088 IGHV4-59*01              
M29812 IGHV4-59*02              
M95114 IGHV4-59*03              
M95117 IGHV4-59*04              
 
St140vκ 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
st140Vk                        gac atc cag atg acc cag tct cca tct tcc gtg tct gca tct gta  
V01577 IGKV1-12*01             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
V01576 IGKV1D-12*02            --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            --- --- --- --- --- --- --- --- --- --t --- --- --- --- ---  
K01323 IGKV1D-16*01            --- --- --- --- --- --- --- --- --c --a c-- --- --- --- ---  
 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
st140Vk                        gga gac aga gtc acc atc act tgt cgg gcg agt cag ggt att agc  
V01577 IGKV1-12*01             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
V01576 IGKV1D-12*02            --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
K01323 IGKV1D-16*01            --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
st140Vk                        agc tgg ... ... ... ... ... ... tta gcc tgg tat cag cag aaa  
V01577 IGKV1-12*01             --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
V01576 IGKV1D-12*02            --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
K01323 IGKV1D-16*01            --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
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st140Vk                        cca ggg aaa gcc cct aag ctc ctg atc tat gct gca tcc ... ...  
V01577 IGKV1-12*01             --- --- --- --- --- --- --- --- --- --- --- --- --- ... ...  
V01576 IGKV1-12*02             --- --- --- --- --- --- --- --- --- --- --- --- --- ... ...  
V01576 IGKV1D-12*02            --- --- --- --- --- --- --- --- --- --- --- --- --- ... ...  
X17263 IGKV1D-12*01            --- --- --- --- --- --- --- --- --- --- --- --- --- ... ...  
K01323 IGKV1D-16*01            --- -a- --- --- --- --- tc- --- --- --- --- --- --- ... ...  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
st140Vk                        ... ... ... ... ... agt ttg caa agt ggg gtc cca ... tca agg  
V01577 IGKV1-12*01             ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
V01576 IGKV1-12*02             ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
V01576 IGKV1D-12*02            ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
X17263 IGKV1D-12*01            ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
K01323 IGKV1D-16*01            ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
 
                               -------------------------------  FR3 - IMGT  --------------- 
                                               80                  85                  90   
st140Vk                        ttc agc ggc agt gga ... ... tct ggg aca gat ttc act ctc acc  
V01577 IGKV1-12*01             --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
V01576 IGKV1D-12*02            --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            --- --- --- --- --- ... ... --- --- --- --- --- --- --- --t  
K01323 IGKV1D-16*01            --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
st140Vk                        atc agc agc ctg cag cct gaa gat ttt gca act tac tat tgt caa  
V01577 IGKV1-12*01             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
V01576 IGKV1D-12*02            --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
K01323 IGKV1D-16*01            --- --- --- --- --- --- --- --- --- --- --- --t --c --c ---  
 
                               __________  CDR3 - IMGT  __________ 
                                
st140Vk                        cag gct aac agt ttc cct cca agc acc ttc ggc caa ggg aca ctc  
V01577 IGKV1-12*01             --- --- --- --- --- --- -- 
V01576 IGKV1-12*02             --- --- --- --- --- --- t- 
V01576 IGKV1D-12*02            --- --- --- --- --- --- t- 
X17263 IGKV1D-12*01            --- --- --- --- --- --- -- 
K01323 IGKV1D-16*01            --- ta- --t --- -a- --- -- 
 
                                
                                
st140Vk                        gag 
V01577 IGKV1-12*01              
V01576 IGKV1-12*02              
V01576 IGKV1D-12*02             
X17263 IGKV1D-12*01             
K01323 IGKV1D-16*01             
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Scu68VH 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
scu68VH                        cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
M29811 IGHV4-61*01             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
X92230 IGHV4-61*03             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
AB019437 IGHV4-61*08           --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
X92250 IGHV4-61*04             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
M29812 IGHV4-59*02             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
scu68VH                        tcg gag acc ctg tcc ctc acc tgc gct gtc tct gga gtc tcc gtc  
M29811 IGHV4-61*01             --- --- --- --- --- --- --- --- a-- --- --- --t -g- --- ---  
X92230 IGHV4-61*03             --- --- --- --- --- --- --- --- a-- --- --- --t -g- --- ---  
AB019437 IGHV4-61*08           --- --- --- --- --- --- --- --- a-- --- --- --t -g- --- ---  
X92250 IGHV4-61*04             --- --- --- --- --- --- --- --- a-- --- --- --t -g- --- ---  
M29812 IGHV4-59*02             --- --- --- --- --- --- --- --- a-- --- --- --t -g- --- ---  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
scu68VH                        gag gat gat act tat tat ... ... tgg acc tgg att cgc cag tcc  
M29811 IGHV4-61*01             agc ag- -g- -g- --c --c ... ... --- -g- --- --c --g --- c--  
X92230 IGHV4-61*03             agc ag- -g- -g- --c --c ... ... --- -g- --- --c --g --- c--  
AB019437 IGHV4-61*08           agc ag- -g- gg- --c --c ... ... --- -g- --- --c --g --- c--  
X92250 IGHV4-61*04             agc ag- -g- -g- --c --c ... ... --- -g- --- --c --g --- c--  
M29812 IGHV4-59*02             agt ag- t-c tac ... ... ... ... --- -g- --- --c --g --- c--  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
scu68VH                        cca ggg aag gga ctg gag tgg att ggc aat gtc tat tac agc ggg  
M29811 IGHV4-61*01             --- --- --- --- --- --- --- --- --g t-- a-- --- --- --t ---  
X92230 IGHV4-61*03             --- --- --- --- --- --- --- --- --g t-- a-- --- --- --t ---  
AB019437 IGHV4-61*08           --- --- --- --- --- --- --- --- --g t-- a-- --- --- --t ---  
X92250 IGHV4-61*04             --- --- --- --- --- --- --- --- --a t-- a-- --- --- --t ---  
M29812 IGHV4-59*02             --- --- --- --- --- --- --- --- --g t-- a-- --- --- --t ---  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
scu68VH                        aca aac ... ... ... tac tac aac ccc tcc ctc gag ... agt cga  
M29811 IGHV4-61*01             -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
X92230 IGHV4-61*03             -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
AB019437 IGHV4-61*08           -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
X92250 IGHV4-61*04             -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
M29812 IGHV4-59*02             -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
 
                               -------------------------------  FR3 - IMGT  --------------- 
                                               80                  85                  90   
scu68VH                        gtc acc gtt tcg ctg gac acg tcc aac aat cag ttc tct ctg aaa  
M29811 IGHV4-61*01             --- --- a-a --a g-a --- --- --- --g --c --- --- --c --- --g  
X92230 IGHV4-61*03             --- --- a-a --a g-a --- --- --- --g --c --c --- --c --- --g  
AB019437 IGHV4-61*08           --- --- a-a --a g-a --- --- --- --g --c --- --- --c --- --g  
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X92250 IGHV4-61*04             --- --- a-a --a g-a --- --- --- --g --c --- --- --c --- --g  
M29812 IGHV4-59*02             --- --- a-a --a g-a --- --- --- --g --c --- --- --c --- --g  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
scu68VH                        ctg agg tct gtg acc tct gcg gac acg gcc ata tat ttt tgt gtg  
M29811 IGHV4-61*01             --- --c --- --- --- g-- --- --- --- --- g-g --- -ac --- -c-  
X92230 IGHV4-61*03             --- --c --- --- --- g-- --- --- --- --- g-g --- -ac --- -c-  
AB019437 IGHV4-61*08           --- --c --- --- --- g-- --- --- --- --- g-g --- -ac --- -c-  
X92250 IGHV4-61*04             --- --c --- --- --. ..c --t --- --- --- g-g --- -ac -- 
M29812 IGHV4-59*02             --- --c --- --- --- g-- --- --- --- --- g-g --- -ac --- -c-  
 
                               _______________________  CDR3 -  IMGT ______________________ 
                                
scu68VH                        aga gat gct tat tat gga ctg ggg tct ccc tca aac tgg ttt gac  
M29811 IGHV4-61*01             --- -- 
X92230 IGHV4-61*03             --- -- 
AB019437 IGHV4-61*08           --- -- 
X92250 IGHV4-61*04              
M29812 IGHV4-59*02             --- -- 
 
                               ___ 
                                
scu68VH                        ccc tgg ggc caa gga ccc ctg gtc aca ggg gtc acc gtc tca agc  
M29811 IGHV4-61*01              
X92230 IGHV4-61*03              
AB019437 IGHV4-61*08            
X92250 IGHV4-61*04              
M29812 IGHV4-59*02              
 
Scu68Vl 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
scu68Vl                        cct tct gag ctg act cag gac cct gct ... gtg tct gtg gcc ttg  
X56178 IGLV3-19*01             t-- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
Z73645 IGLV3-32*01(ORF)        t-c --- -g- -ca --- --- -tg --- --a ... --- --- --- --- ---  
X57826 IGLV3-1*01              t-c -a- --- --- --- --- cca --c t-a ... --- --c --- t-- cca  
X97473 IGLV3-9*01              t-c -a- --- --- --- --- cca -tc t-a ... --- --a --- --- c--  
M94116 IGLV1-40*01             -ag --- -t- --- --g --- ccg --c t-a ... --- --- -g- --- cca  
 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
scu68Vl                        ggg cag aca gtc aca atc aca tgc cag gga gac agc ctc aaa agg  
X56178 IGLV3-19*01             --a --- --- --- -gg --- --- --- --a --- --- --- --- -g- --c  
Z73645 IGLV3-32*01(ORF)        --a --a -tg -c- -gg --- --c --- --- --- --- --- a-g g-- g-c  
X57826 IGLV3-1*01              --a --- --- -c- -gc --- --c --- tct --- --t -aa t-g ggg gat  
X97473 IGLV3-9*01              --a --- --g -c- -gg --t --c --t gg- --- a-- -a- a-t gg- --t  
M94116 IGLV1-40*01             --- --- -gg --- --c --- t-c --- act --g ag- --- tc- --c -tc  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
scu68Vl                        tat tat ... ... ... ... ... ... gca ggc tgg tat aag cag aag  
 86 
X56178 IGLV3-19*01             --- --- ... ... ... ... ... ... --- a-- --- --c c-- --- ---  
Z73645 IGLV3-32*01(ORF)        -c- --- ... ... ... ... ... ... -a- ca- --- --c c-- --- ---  
X57826 IGLV3-1*01              a-a --- ... ... ... ... ... ... --t t-- --- --- c-- --- ---  
X97473 IGLV3-9*01              a-a a-- ... ... ... ... ... ... -tg ca- --- --c c-- --- ---  
M94116 IGLV1-40*01             ggg gca ggt tat gat ... ... ... -t- ca- --- --c c-- --- ctt  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
scu68Vl                        cca gga cag gcc cct caa ctt gtc att tat gct aaa aac ... ...  
X56178 IGLV3-19*01             --- --- --- --- --- gt- --- --- --c --- -g- --- --- ... ...  
Z73645 IGLV3-32*01(ORF)        --- --c --- --- --c gtg --g --- --c --- -a- -gc -gt ... ...  
X57826 IGLV3-1*01              --- --c --- t-- --- gtg --g --- --c --- caa g-t -g- ... ...  
X97473 IGLV3-9*01              --- --c --- --- --- gtg --g --- --c --- agg g-t -g- ... ...  
M94116 IGLV1-40*01             --- --- aca --- --c a-- --c c-- --c --- -g- --c -g- ... ...  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
scu68Vl                        ... ... ... ... ... agg cgg ccc tca ggg atc cca ... gac cga  
X56178 IGLV3-19*01             ... ... ... ... ... -ac --- --- --- --- --- --- ... --- ---  
Z73645 IGLV3-32*01(ORF)        ... ... ... ... ... gac --- --- --- a-- --- --t ... --g ---  
X57826 IGLV3-1*01              ... ... ... ... ... -a- --- --- --- --- --- --t ... --g ---  
X97473 IGLV3-9*01              ... ... ... ... ... -ac --- --- --t --- --- --t ... --g ---  
M94116 IGLV1-40*01             ... ... ... ... ... -at --- --- --- --- g-- --t ... --- ---  
 
                               -------------------------------  FR3 - IMGT  --------------- 
                                               80                  85                  90   
scu68Vl                        ttc tct ggg tcc aac ... ... tca gga gac aca gcc tcc ttg acc  
X56178 IGLV3-19*01             --- --- --c --- -g- ... ... --- --- a-- --- --t --- --- ---  
Z73645 IGLV3-32*01(ORF)        --- --- --c --- --a ... ... --- --c a-- --- a-- a-- c-- ---  
X57826 IGLV3-1*01              --- --- --c --- --- ... ... --t --g a-- --- --- a-t c-- ---  
X97473 IGLV3-9*01              --- --- --c --- --- ... ... --g --g a-- --g --- a-- c-- ---  
M94116 IGLV1-40*01             --- --- --c --- --g ... ... --t --c ac- t-- --- --- c-- g--  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
scu68Vl                        atc act ggg gct cag gcg gaa gat gag gct gaa tat ttc tgt aat  
X56178 IGLV3-19*01             --- --- --- --- --- --- --- --- --- --- --c --- -a- --- --c  
Z73645 IGLV3-32*01(ORF)        --- --- --- --c --- --t --g --- --- --- --t --- -a- -a- c-g  
X57826 IGLV3-1*01              --- -gc --- a-c --- --t atg --- --- --- --c --- -a- --- c-g  
X97473 IGLV3-9*01              --- -gc a-a --c --a --c -gg --- --- --- --c --- -a- --- c-g  
M94116 IGLV1-40*01             --- --- --- ctc --- --t --g --- --- --- --t --- -a- --c c-g  
 
                               ______________  CDR3 - IMGT  ______________ 
                                
scu68Vl                        tcc cgc gac ggc ttt gaa aat cat cgg gtg ctt ttc ggc gga ggc  
X56178 IGLV3-19*01             --- --g --- a-- ag- -gt --c --- -t 
Z73645 IGLV3-32*01(ORF)        -tg ata --- aa- ca- -ct -c 
X57826 IGLV3-1*01              g-g t-g --- a-- agc act gca 
X97473 IGLV3-9*01              gtg t-g --- a-- agc act gca 
M94116 IGLV1-40*01             --- tat --- a-- agc ctg -g- gg- tc 
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scu68Vl                        acc aag ctg acc gtc ctc gag 
X56178 IGLV3-19*01              
Z73645 IGLV3-32*01(ORF)         
X57826 IGLV3-1*01               
X97473 IGLV3-9*01               
M94116 IGLV1-40*01              
 
For the ELISA against proteinase-3 we developed a positive control based on an article by J. 
Davis3. The immunoglobulin sequence coding for the variable heavy and light chain domains 
which is shown in this article is specific for proteinase-3. It was, however, not complete 
because the first 8 codons were missing. To produce a fab based on this sequence Doctor 
Csernok (Bad Bramstedt, Germany), kindly sent us a hybridoma which produces antibodies 
and which uses the sequence given in the aforementioned article. We ran a PCR on the cell 
culture material using primers which attach to the sequences and which add the restriction 
enzyme recognition sites used to clone the DNA coding for the heavy and light variable 
domains. This positive control is called “Pr3pos”, it has a lambda light-chain and the primers 
are shown here: 
 
Pr3pos heavy chain primers: 
5’-first 
CAG GTG CAG CTG GTG GAG TCT () GGG GGA GGC GTG GTC CAG CC (72°C) 
 
5’-second 
gcG GCC CAG CCG GCC ATG GCC () CAG GTG CAG CTG GTG GAG TCT G (72°C) 
 
5’-third 
GGG GGG () GCG GCC CAG CCG GCC ATG GC (74°C) 
 
3’-primer 
GGG GGG GAGGAGACGGTGACCAGGGTTC (74°C) 
 
Pr3pos light chain primers 
 
5’-light chain 
GGG GGG G GTG CA () CAG TCT GCC CTG ACT CAG CCT G (72°C) 
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3’-light chain 
GGG GGG CTCGAGGACGGTCAGCTTGGTCCCTCCG 
 
The resulting sequence is shown below: 
 
Sequence of the proteinase-3 positive control. 
This sequence is based on Davis.3 
 
Pr3posVH 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
Pr3posvh                       cag gtg cag ctg gtg gag tct ggg gga ... ggc gtg gtc cag cct  
M99663 IGHV3-30*03             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
X92214 IGHV3-30*18             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
L06616 IGHV3-30*19             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
M77334 IGHV3-33*05             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
M77339 IGHV3-30*13             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
Pr3posvh                       ggg agg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttc  
M99663 IGHV3-30*03             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
X92214 IGHV3-30*18             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
L06616 IGHV3-30*19             --- --- --- --- --- --- --- --- --- --g --- --- --- --- ---  
M77334 IGHV3-33*05             --- --- --- --- --- --- --- --- --- --g --- --- --- --- ---  
M77339 IGHV3-30*13             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
Pr3posvh                       agt agc tat ggc ... ... ... ... atg cac tgg gtc cgc cag gct  
M99663 IGHV3-30*03             --- --- --- --- ... ... ... ... --- --- --- --- --- --- ---  
X92214 IGHV3-30*18             --- --- --- --- ... ... ... ... --- --- --- --- --- --- ---  
L06616 IGHV3-30*19             --- --- --- --- ... ... ... ... --- --- --- --- --- --- ---  
M77334 IGHV3-33*05             --- --- --- --- ... ... ... ... --- --- --- --- --- --- ---  
M77339 IGHV3-30*13             --- --- --- --- ... ... ... ... --- --- --- --- --- --- ---  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
Pr3posvh                       cca ggc aag ggg ctg gag tgg gtg gca gtt ata tca tat gat gga  
M99663 IGHV3-30*03             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
X92214 IGHV3-30*18             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
L06616 IGHV3-30*19             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
M77334 IGHV3-33*05             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
M77339 IGHV3-30*13             --- --- --- --- --a --- --- --- --- --- --- --- --- --- ---  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
Pr3posvh                       agt aat aaa ... ... tac tat gca gac tcc gtg aag ... ggc cga  
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M99663 IGHV3-30*03             --- --- --- ... ... --- --- --- --- --- --- --- ... --- ---  
X92214 IGHV3-30*18             --- --- --- ... ... --- --- --- --- --- --- --- ... --- ---  
L06616 IGHV3-30*19             --- --- --- ... ... --- --c --- --- --- --- --- ... --- ---  
M77334 IGHV3-33*05             --- --- --- ... ... --- --- --- --- --- --- --- ... --- ---  
M77339 IGHV3-30*13             --- --- --- ... ... --- --c --- --- --- --- --- ... --- ---  
 
                               -------------------------------  FR3 - IMGT  --------------- 
                                               80                  85                  90   
Pr3posvh                       ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg caa  
M99663 IGHV3-30*03             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
X92214 IGHV3-30*18             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
L06616 IGHV3-30*19             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
M77334 IGHV3-33*05             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
M77339 IGHV3-30*13             --- --- --- --- --- --- --- --- --- --- -g- --- --- --- ---  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
Pr3posvh                       atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt gcg  
M99663 IGHV3-30*03             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
X92214 IGHV3-30*18             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
L06616 IGHV3-30*19             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
M77334 IGHV3-33*05             --- --- --- --- --- --c --- --- --- --- --- --- --- --- ---  
M77339 IGHV3-30*13             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
 
                               ___________________________________  CDR3 -  IMGT __________ 
                                
Pr3posvh                       aag agc caa atg tcg tat tac gat ttt tgg agt ggt tat tac cgg  
M99663 IGHV3-30*03             -ga ga 
X92214 IGHV3-30*18             --a ga 
L06616 IGHV3-30*19             -ga ga 
M77334 IGHV3-33*05             -ga ga 
M77339 IGHV3-30*13             -ga ga 
 
                               ___________________________ 
                                
Pr3posvh                       gac cag tac tac ttt gac tac tgg ggc cag gga acc ctg gtc acc 
M99663 IGHV3-30*03              
X92214 IGHV3-30*18              
L06616 IGHV3-30*19              
M77334 IGHV3-33*05              
M77339 IGHV3-30*13              
 
Pr3posVl 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
Pr3posvl                       cag tct gcc ctg act cag cct gcc tcc ... gtg tct ggg tct cct  
Z73664 IGLV2-14*01             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
L27822 IGLV2-14*02             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
Z73665 IGLV2-23*02             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
Y12412 IGLV2-14*03             ... ... ... ... ... ... ... ..- --- ... --- --- --- --- ---  
D86994 IGLV2-23*03             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
 
 90 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
Pr3posvl                       gga cag tcg atc acc atc tcc tgc act gga acc agc agt gac gtt  
Z73664 IGLV2-14*01             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
L27822 IGLV2-14*02             --- --- --- --- --- --- --- --- --- --- --- --- --- --t ---  
Z73665 IGLV2-23*02             --- --- --- --- --- --- --- --- --- --- --- --- --- --t ---  
Y12412 IGLV2-14*03             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
D86994 IGLV2-23*03             --- --- --- --- --- --- --- --- --- --- --- --- --- --t ---  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
Pr3posvl                       ggt ggt tat aac tat ... ... ... gtc tcc tgg tac caa caa cac  
Z73664 IGLV2-14*01             --- --- --- --- --- ... ... ... --- --- --- --- --- --g ---  
L27822 IGLV2-14*02             --g a-- --- --- ct- ... ... ... --- --- --- --- --- --g ---  
Z73665 IGLV2-23*02             --g a-- --- --- ct- ... ... ... --- --- --- --- --- --g ---  
Y12412 IGLV2-14*03             --- --- --- --- --- ... ... ... --- --- --- --- --- --- ---  
D86994 IGLV2-23*03             --g a-- --- --- ct- ... ... ... --- --- --- --- --- --g ---  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
Pr3posvl                       cca ggc aaa gcc ccc aaa ctc atg att tat gat gtc agt ... ...  
Z73664 IGLV2-14*01             --- --- --- --- --- --- --- --- --- --- --g --- --- ... ...  
L27822 IGLV2-14*02             --- --- --- --- --- --- --- --- --- --- --g -g- --- ... ...  
Z73665 IGLV2-23*02             --- --- --- --- --- --- --- --- --- --- --g --- --- ... ...  
Y12412 IGLV2-14*03             --- --- --- --- --- --- --- --- --- --- --- --- --- ... ...  
D86994 IGLV2-23*03             --- --- --- --- --- --- --- --- --- --- --g -g- --- ... ...  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
Pr3posvl                       ... ... ... ... ... aat cgg ccc tca ggg gtt tct ... aat cgc  
Z73664 IGLV2-14*01             ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
L27822 IGLV2-14*02             ... ... ... ... ... --g --- --- --- --- --- --- ... --- ---  
Z73665 IGLV2-23*02             ... ... ... ... ... --g --- --- --- --- --- --- ... --- ---  
Y12412 IGLV2-14*03             ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
D86994 IGLV2-23*03             ... ... ... ... ... --g --- --- --- --- --- --- ... --- ---  
 
                               -------------------------------  FR3 - IMGT  --------------- 
                                               80                  85                  90   
Pr3posvl                       ttc tct ggc tcc aag ... ... tct ggc aac acg gcc tcc ctg acc  
Z73664 IGLV2-14*01             --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
L27822 IGLV2-14*02             --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
Z73665 IGLV2-23*02             --- --- --- --- --- ... ... --- --- --- --- --- --- --- --a  
Y12412 IGLV2-14*03             --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
D86994 IGLV2-23*03             --- --- --- --- --- ... ... --- --- --- --- --- --- --- --a  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
Pr3posvl                       atc tct ggg ctc cag gct gag gac gag gct gat tat tac tgc agc  
Z73664 IGLV2-14*01             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
L27822 IGLV2-14*02             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
Z73665 IGLV2-23*02             --- --- --- --- --- --- --- --- --- --- --- --- --- --- t--  
Y12412 IGLV2-14*03             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
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D86994 IGLV2-23*03             --- --- --- --- --- --- --- --- --- --- --- --- --- --- t--  
 
                               __________  CDR3 - IMGT  __________ 
                                
Pr3posvl                       tca tat aca agc agc agc act gaa gtg ttc ggc gga ggg acc aag  
Z73664 IGLV2-14*01             --- --- --- --- --- --- --- ctc 
L27822 IGLV2-14*02             --- --- --- --- --- --- --- ctc 
Z73665 IGLV2-23*02             --- --- g-- g-t --t --- --- ttc 
Y12412 IGLV2-14*03             --- --- --- --- --- --- --- ctc 
D86994 IGLV2-23*03             --- --- g-- g-t --t --- --- ttc 
 
                                
                                
Pr3posvl                       ctg acc gtc ctc gag 
Z73664 IGLV2-14*01              
L27822 IGLV2-14*02              
Z73665 IGLV2-23*02              
Y12412 IGLV2-14*03              
D86994 IGLV2-23*03              
 
After we added the missing codons and added the restriction enzyme recognition sites we 
cloned the light and heavy chain DNA segments into the Pces1 vector as described in 
“Materials and methods”. 
 
We then proceeded to produce Fab Fragments as described in Methods which yielded the 
following protein quantities: 
 
Table 7:  Fab Fragments and their yield per liter of inoculated bacterial culture. 
Fab-Fragment Quantity per liter of 
bacterial culture 
PR3Pos 1 mg 
Scu68 1 mg  
St140 Negligible 
 
As can be seen from table 7, both the Fab-Fragment PR3-Pos and Scu68 could be produced in 
a quantity of 1 mg per liter of culture inoculated with the plasmid containing bacteria as 
described in Methods under “Production of Fabs using the Pces1 Vector”. The St140 Fab 
could not be produced in any significant quantities. We therefore continued integrity testing 
with the PR3pos and Scu68 Fab fragments. 
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4.2 Integrity testing of Fab Fragments using SDS-PAGE 
 
The Scu68 and PR3pos Fab fragments underwent denaturation under both reducing and non-
reducing conditions and underwent separation based on molecular weight using the method of 
SDS-PAGE as described unter “Methods”. Also, a protein mixture with proteins of known 
molecular weight was loaded onto the polyacrylamid gel as a reference “ladder”.  The results 
are shown in the figure below. 
 
Figure 31:  
Results of SDS-PAGE analysis after staining with Coomassie 
 
We can see in figure 31 that both the PR3pos and Scu68 Fab fragments in reduced and 
unreduced form were loaded onto the polyacrylamid gel and separated by electrophoresis. 
Thereafter the gel was stained using Coomassie blue. In non-reduced form the Fab migrated 
in the gel over a distance corresponding to a molecular mass of approximately 50 kDa. In the 
reduced form, where the disulfide bonds which connect heavy and light chain have been 
dissolved, a band of approximately 30 kDa appeared. Since heavy and light chain in a Fab 
fragment are of comparable size only a single band appears under reducing conditions. The 
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pattern which appears here is consistent with the pattern produced by Fab fragments with 
known integrity and functionality used in our laboratory. This proves that our Fab Fragments 
are intact and, thus, that the construction of Fab fragments through cloning is possible.  
 
4.3 Western blotting 
 
To further test the integrity of the Fab Fragments we performed Western blotting as described 
in “Methods”. The proteins were transferred to a PVDF membrane using the semi-dry 
method. We then incubated with the mouse anti-Penta-His IgG antibody followed by goat 
anti-mouse IgG antibody (peroxidase coupled) which is a cascade specific for the heavy-
chain. Separately we also incubated with the rabbit anti-human-lambda IgG followed by the 
peroxidase coupled anti-rabbit IgG which is a cascade specific for the light-chain, since both 
Fab fragments tested here are of the λ variety. After incubation with the peroxidase substrate 
the following result was obtained. 
  
 
Figure 32: 
Western Blot after incubation with the heavy chain cascade, see text 
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In figure 32 the result of our Western blot is shown for both the denatured samples, shown 
here as non-reduced and for the samples which, in addition to denaturation through incubation 
with SDS gel-loading buffer were also reduced, thereby breaking the disulfide bridges. Under 
non-reducing conditions we saw a band at about 50 kDa, consistent with the known size of a 
non-reduced Fab fragment, where light and heavy chain are still together. Under reducing 
conditions the light and heavy chain are no longer held together, but since they are of 
comparable size still only one band appeared in the Western blot under reducing conditions, 
as shown in the image. This one band contained both light and heavy chains. In the figure 
above the result of Western blotting with the heavy chain cascade is shown. The results of 
Western blotting with the light chain cascade was exactly identical because light and heavy 
chain are of similar molecular weight.  
 
The Western blot further proves that our Fab fragment was intact. The antibodies used reacted 
with the His-Tag, which is located in the heavy chain and they reacted with an anti-lambda 
antibody which is specific for human λ light chain. 
 
4.4 ELISA testing 
 
To check if the coating was done correctly we used the antibody positive controls and a serum 
positive for PR3-ANCAs of a commercially available PR3-ANCA kit to perform an ELISA 
using a PR3 coated plate. 
The results are shown here. 
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Figure 33: 
ELISA results using a commercially available kit with our PR3-coated ELISA plate. X-Axis: 
various probes, see text.  Y-Axis: OD450  
 
The commercially available kit contains an antibody of unknown origin specific for PR3 in 
increasing concentrations, labelled “Calib” 0-100 here. It also contains a human serum 
containing an ANCA with specificity for PR3, labelled “+” here and a human serum which 
serves as a negative control, labelled “-“ here. The Calib 0-100 probes serve as a calibration 
tool for the test and in this case it proved that our PR3-protein was intact and that it reacted 
with the positive controls of the commercially available kit.  
 
Thereafter we performed an ELISA as described under “methods” using a coating of PR3-
protein and our PR3Pos and Scu68 fabs as primary antibodies. The antibody whose DNA-
sequence was used to make our PR3pos fab fragment was isolated from a bacterial culture 
producing this antibody and was also used in the ELISA. This antibody is called WGH1 
below. 
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Figure 34: 
Results of ELISA testing against a PR3 coating using various antibodies and fab fragments 
 
We used the PR3Pos fab fragment in a concentration of 10 µg/ml, the Scu68 Fab fragment in 
a concentration of 16 µg/ml. As a negative control we used a lambda Fab fragment with 
specificity for the influenza matrix protein in an MHC complex, this Fab fragment is called 
2F3A7 in the figure above. As a second negative control we used a Fab fragment with the 
same IMP-MHC specificity which was of the Kappa variety, this Fab fragment is designated 
“Kappa” in the figure above. The WGH1 antibody is called WGH1 in the figure above and is 
a full antibody. Additionally we used the positive and negative controls from the 
commercially available kit used for ANCA testing in the routine patient laboratory, called 
“Kitpos” and “Kitneg” in the figure above. We also performed an ELISA without any 
antibody, incubating only with PBS in 1% BSA, this test is called “neg” in the figure above.  
 
As can be seen from the figure above the WGH1 antibody reacts to the PR3 coating. Also the 
positive control from the commercial kit reacts to the PR3 coating. The PR3Pos Fab fragment 
does not react against the PR3 protein. The Scu68 fab fragment also does not react against the 
PR3 protein, although the signal is somewhat higher which might be due to the higher 
concentration which was used, representing aspecific binding. 
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This proves that also in this ELISA the coating with PR3 was successful and the PR3 protein 
was intact after coating. The WGH1 antibody displays specificity for the PR3 protein, as 
expected. Our PR3Pos Fab fragment does not bind to PR3 protein, even though the DNA 
sequence used for producing this Fab fragment was identical to the DNA sequence of the 
WGH1 antibody, with proven specificity for PR3. 
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5. Discussion 
 
As has been described above, Wegener’s granulomatosis basically consists of two entities. 
The granulomatous lesions mainly occur in the respiratory tract. Often the granulomatous 
disease is followed by a systemic small-vessel vasculitis which probably is caused by 
antibodies against PR3. There is a clear chronological order in which these two entities occur. 
This chronology is the strongest argument for Fienberg’s hypothesis, which states that the 
granulomas eventually give rise to the systemic vasculitis. Opponents of this theory might 
argue that the early nidi of necrosis out of which the granulomas arise are themselves a 
consequence of a systemic vasculitis. 
  
Evidence for Fienberg’s hypothesis has been accumulating in recent years33. B-cell clusters 
have been observed in the granulomatous lesions found in Wegener’s granulomatosis and 
DNA-analysis of B-cells found in these clusters has shown clonal expansion which is 
indicative of a germinal center where antigen-driven affinity maturation takes place and 
therefore represents ectopic lymphoid tissue. On the other hand it is known that the cANCAs 
are central in the pathogenesis of the systemic vasculitis seen in Wegener’s granulomatosis. 
The B-cells which produce these ANCAs underwent affinity maturation somewhere because 
they are of the IgG type and it also known that PR3 is found in the vicinity of the B-cell 
clusters in the granulomatous lesion33.  
 
Our hypothesis is that formation of the cANCA producing B-cells takes places within the 
granulomatous lesions seen in Wegener’s granulomatosis and that PR3 is the antigen on 
which this affinity maturation takes place. 
 
Our goal was to produce antibodies, which are similar to the B-cell receptor from antigen (e.g. 
PR3) – selected B-Lymphocytes that had been isolated from granulomatous WG tissues in 
order to determine their specificity. We started out with DNA material isolated from 
individual B cells. First we determined the exact sequence of the DNA material which was 
present in our samples. In multiple rounds of PCR the variable heavy and light chain coding 
genes were amplified. We cloned these PCR products into the TOPO-vector which allowed 
sequencing. The results of sequencing showed that most DNA coding for the heavy chains 
were lacking the 5’ beginning of the framework region. We fixed this problem by 
supplementing these DNA-fragments with DNA-segments homologous to the respective 
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germline gene. Furthermore, we added the restriction enzyme recognition sites which were 
needed to clone the the DNA into the Pces1 vector. This meant adding more nucleotides than 
is possible in one PCR reaction. In fact, we needed up to four PCR reactions in some cases. 
As a new approach we mixed the different primers together and performed the PCR reaction 
in one step. This yielded very mixed results. With some products we could indeed add all 
nucleotides in one step and with some others the final primer did not bind or the entire 
reaction did not succeed. If the PCR was not successful the process had to be repeated step by 
step. Since the success ratio of mixing the primers is not very high the reduction in time and 
labour was only limited. 
 
In the end we succeeded in cloning all of the DNA coding for the variable domain of the 
heavy and light chains into the pCes1 vector. This allowed us to produce Fab fragments. 
 
This method represents a totally new approach in handling Fab fragments. Up to now the 
pCes1 vector was used to mass produce an almost endless array of Fab fragments of different 
specificities with the goal of isolating a Fab fragment with known specificity using the 
following method. First random DNA sequences coding for heavy and light chains are mass 
cloned into the pCES1 vector and then these vectors are mass transformed into the appropriate 
bacterial cultures. The Fab fragments were expressed as a fusion protein connected to a 
complete phage, which contained the pCes1 vector and therefore the DNA coding for the Fab 
Fragment. In this way a solid link between the recombinant protein and the DNA coding for 
this recombinant protein was achieved. The collection of phage with many different random 
Fab fragments on their surface is an example of a phage library. The Fab fragments have a 
multitude of different specificities. Using this phage library a series of ELISAs are performed 
where the phage are first allowed to bind to a selected protein through the Fab fragment which 
they express on their surface, after which non-binding phage are washed away. Binding phage 
were eluted and amplified in E. Coli for the next round of ELISA. In the end phage expressing 
Fab fragments with specificity for the protein used in the ELISA can be derived. The phage 
library in this case was a random phage library expressing Fab fragments which have either a 
random specificity or are dysfunctional. Through multiple rounds of ELISAs the derivation of 
Fab fragments with specificity for the protein used to coat the ELISA plates was possible. 
Phage libraries can also be used in other experiments, not involving Fab fragments. In another 
method, a phage library which is derived from the genome of a certain bacterial or 
mammalian genome, a socalled “natural” peptide library, which is constructed by cleaving 
 100 
DNA from the appropriate species into the appropriate size and mass cloning the DNA 
fragments into the pCes1 vector, can be used to present a very wide array of proteins to an 
antibody of unknown specificity. Through ELISA testing the specificity of this antibody can 
then be determined. It should be noted, however, that glycosylation, which takes places 
frequently in mammalian proteins, is not performed using the pCES1 Vector system, since it 
is a bacterial system, in which glycosylation does not take place.  Of course, a random phage 
library can also contain random proteins, as well as randomly created Fab fragments, which 
just depends on what is cloned into the pCES-1 vector. These are two different 
implementations of the phage diplay technology. In the first a library of Fab fragments with 
different specificities is produced, yielding Fab fragments of known specificity after a process 
called ‘panning’ against a known protein. In the second implementation the phage display 
technology is used to present a specific antibody with a vast array of proteins, either randomly 
generated or, as in a natural library, derived from the genome of bacteria or mammals. 
Through the first method described above, Fab fragments are selected based upon binding 
affinity to the protein under investigation. The phage and Fab fragments obtained through this 
procedure display a proven integrity, otherwise they could not have been selected through 
binding in the ELISA.  
 
Our approach was different and new. We have not obtained our Fab fragment through 
selection, which guarantees binding capability and integrity. We have constructed our Fab 
fragments on the basis of DNA information derived from a B-cell coding for a full antibody 
and on the basis of DNA information derived from a hybridoma producing an antibody with 
known specifity for PR3. We could not assume that our Fab fragments are structurally intact 
because the way in which they were produced is very different from the selection described 
above. Of note, our Fab fragments were constructed based upon information from single B 
cells and consecutively are of unknown specificity, which is another difference from the 
method described above. The aim of our study was to investigate the specifity of B cell 
receptors found in the granulomatous lesions found in Wegener’s granulomatosis patients. As 
a proof-of-principle we first investigated the structural integrity of the Fab fragments we 
produced. As a second step we investigated the binding capacity of our positive control, 
called PR3pos, to the PR3 protein, using ELISA.  
The first step was necessary because our Fab fragment was a hybrid; The DNA coding for the 
variable regions was derived from our B cells or antibody-producing hybridoma cell line 
while the constant regions were in the pCES-1 vector itself. Therefore it was not certain that 
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this hybrid still had the same structure as as Fab fragment, since there are many transitional 
regions in the DNA coding for an antibody as a result of VDJ rearrangement. These 
transitional regions might also be involved in protein folding. The second step was necessary 
to investigate if the intact Fab fragment retains the same specificity as the full antibody it was 
derived from. This is not certain. The Fab fragment is similar to a full antibody, but the Fc 
fragment is missing, which might cause a conformational change and change of specificity. 
The same is true for the Fab fragments which are derived using selection as described above. 
These Fab fragments might not bind to the protein upon which they were selected if they were 
produced as full antibodies. In order to answer the question of retention of specificity when 
removing or adding the Fc-fragment it is very important to have a positive control based on an 
antibody with known specificity. For this purpose we set out to construct a Fab fragment with 
specificity for the PR3 protein. We isolated the DNA from a hybridoma which produces an 
anti-PR3 antibody. We cloned this DNA into our Pces1 vector just like we did for the DNA 
which was isolated from the B-cells. The DNA sequence of the DNA we derived from the 
hybridoma was exactly identical to the DNA sequence which was described in a paper3 about 
a PR3-specific antibody, derived from a Wegeners granulomatosis patient, called WGH1.  
 
We proved the integrity of our Fab fragments by two different methods. In a first step we used 
SDS-PAGE to investigate the molecular weight of the proteins we produced. The molecular 
weight we found was comparable to Fab fragments with known integrity and proven binding 
capability. Under reducing circumstances the bands in our gel were found at a level 
corresponding to a protein size of about 30 kDa, which is consistent with the results of Fab 
fragments with known integrity. We conclude that our protein consist of two parts which can 
be separated under circumstances which break up disulfide bridges. These two parts probably 
represent heavy and light chain. To further prove this idea we used Western blotting with 
immunological probing by two different blotting approaches. We used two different 
development cascades in our Western blots. One was specific for His-Tag known to be 
present in the heavy chain of Fab Fragments produced using the pCES-1 vector as used in our 
experiments and the other cascade was very specific for the human lambda light chain. The 
results were identical to results derived from Western blotting using Fab fragments with 
known integrity and binding capability. The antibodies bound specifically to heavy and light 
chain which in the end proves the integrity of our Fab fragments definitively. 
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Regarding the question of preservation of specificity when producing a Fab fragment based 
on information derived from a full antibody we performed an ELISA using the PR3 protein. 
In a first step we proved that the coating of the ELISA plates using our PR3 was successful 
using a commercially available kit used for determination of the ANCA-titer in the clinical 
laboratory. After that we used our PR3pos Fab fragment to test for specificity for the PR3 
protein. Additionally we used our Scu68 Fab fragment to test for specificity against PR3. As 
shown in the last figure in the Results chapter our PR3Pos fab fragment did not bind to PR3. 
At the same time the full antibody from which the DNA sequence was derived to produce this 
fab fragment did bind to PR3. This proves that the DNA sequence is coding for a PR3 binding 
antibody. Above, we also showed that our fab fragments are structurally intact and we 
checked that we correctly cloned the DNA coding for the variable regions of the WGH1 
antibody into our Pces1 vector. Therefore, it is certain that we have an intact fab fragment 
with a protein sequence identical to the protein sequence of the variable part of the WGH1 
antibody which binds PR3 protein. Still our fab fragment does not bind PR3. The most 
probable explanation for the Fabs non-affinity to PR3 is a conformational change due to the 
lack of a Fc-receptor or a different tertiary structure in the Fab fragment. 
 
A review of PR3-binding antibodies was given by E. Peen and R.C. Williams jr21. In a table 
derived from this review we hereby show the aminoacid sequence of some PR3-binding 
antibodies, data derived from Davis3 and Sibilia28.  
 
Table 8: PR3-binding antibodies and their characteristics. 
Designation VH CDR3 sequence VL CDR3 sequence 
WGH13 SQMSYYDFWSGYYRDQYY SSYTSSSTEV 
WG128 VAVAGGFDPWGQGTLVT  
WG228 GEIDFWSGYFREGLVGP EDFATYYCLQHNSYP 
WG328 RGIFEGSGYYALDDWGQG QQYYGTPFTFGPGTKVDIKR 
WG428 SRGTSCYMSCDCWGPRTL QQHYGTPFTFGTKVDIKR 
 
The WGH1 is the sequence of our pr3pos-fab. As reviewed in Peen and Williams21 the 
negatively charged glutamic acids (E) and aspartic acids (D) are multiply present in the 
aminoacid sequence. This is consistent with the findings of our group, Voswinkel et al31,33 
who found a skewing towards negatively charged aminoacids in the immunoglobulin coding 
sequences found in granulomatous formations in WG patients. It is evident that there is 
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considerable variation in the aminoacid sequence of published PR3-binding antibodies. The 
PR3-antibody we used to produce our Fab had less negatively charged aminoacids and is 
therefore a little different from the other PR3-antibodies. Comparative studies investigating 
the affinity of PR3-antibodies have not been published. Further, no quantitative studies 
analysing the nature of the PR3-binding antibodies in sera from WG-patients have been 
performed.  
 
Our method represents a new approach in handling Fab fragments. Other groups performed 
screening of millions of randomly formed Fabs displayed on phage against the protein of 
interest using an ELISA plate with washing steps. Only those phage displaying Fabs that bind 
to the coated protein are used to perform further studies. In this situation two things are 
known. First, the Fab fragments are functional and bind to a certain protein. Secondly, the 
protein to which the Fab fragments binds is known. We had a completely different approach: 
we isolated DNA coding from whole antibodies and used this DNA to construct Fab 
fragments. We did not know the specificity of these Fab fragments and because we 
constructed these fragments instead of selecting them out of a library using ELISAs we also 
did not know if these Fab fragments are functional. Put simply, a Fab fragment is an antibody 
without the Fc fragment. Because the Fc fragment is lacking, the variable domain might have 
a slightly different folding or orientation which might alter the specificity or disable 
functionality as a whole. This possibility cannot be excluded and might explain the inability 
of the PR3Pos fab to bind the PR3 protein. At the moment our group is developing a system 
to produce whole antibodies instead of Fab fragments with the intention of repeating ELISA 
screening and performing phage library screening. By producing whole antibodies we get 
closer to the human disease in which ANCAs typically are IgG antibodies. 
  
In summary, we succeeded in preparing DNA derived from B cells from granulomatous 
lesions of Wegeners patients and successfully used this DNA to produce intact Fab fragments 
with a variable region protein sequence which is identical with the antibody or B-cell receptor 
produced by the respective single B cell from which the DNA was derived. Either due to 
conformational changes caused by the removal of the Fc Fragment in a Fab fragment or due 
to a different tertiary structure of the Fabs as compared to the whole antibody our fabs failed 
to bind a protein target. Another explanation is that the specificity of the Fab fragment has 
changed due to the replacement of nucleotides which were lost in the PCR reactions 
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performed after capture of single B cells with germline sequence, although this is unlikely 
since the highly variable complementary determining regions were preserved.  
 
Perspectives 
As described above, further work is currently being undertaken to produce full antibodies 
instead of mere Fab fragments which will presumably answer this question. This study laid 
the groundwork for these efforts, which will help to investigate the nature of the B cell 
receptors found in granulamatous lesions of Wegeners patients and elucidate their precise 
role. It is possible that our hypothesis, which states that the anti-PR3 antibody arises in the 
granulomas found in the respiratory tract, will be confirmed, which will lead to a profound 
understanding of the still rather unclear pathophysiologic mechanisms leading to this disease. 
On the other hand, the characterization of the specificity of the B cell receptors found in the 
respiratory tract lesions might lead to the identification of other antigens which might play a 
role in pathophysiology. There is, for instance, no clear explanation for the protective effect of 
cotrimoxazol treatment. Treatment with co-trimoxazole leads to a significant reduction in 
respiratory tract and other infections and leads to a significant reduction in the incidence of 
relapse in WG patients who are in remission. At the same time there is an association between 
chronic nasal carriage of Staph. aureus and relapse rates in WG. If the B cell receptors would 
turn out to be specific for parts of the Staph. aureus bacterium these findings could be better 
understood. Possibly, other pathogenic agents might be identified. Whatever the target of the 
B cells found in the granulamatous lesions of WG patients might be, it is clear that its 
characterization will lead to a much better understanding of the underlying pathophysiology 
and open the road to new therapeutic possibilities. As an example, once pivotal antigens in the 
genesis of granulomatous lesions found in Wegeners granulomatosis have been identified, 
blocking these antigens with an in vitro produced antibody (analogous to the anti CD-20 
antibody known as Rituximab) would deprive the B cells found in the granulomatous lesions 
of stimulation, possibly leading to an interruption of the inflammatory process and 
inducement of a remission. 
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Appendix I: Results of sequencing  
 
St140 VH 
 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
st140vh                        ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
L10088 IGHV4-59*01             cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
M29812 IGHV4-59*02             cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
X56360 IGHV4-59*07             cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
M95114 IGHV4-59*03             cag gtg cag ctg cag gag tcg ggc cca ... gga ctg gtg aag cct  
X87091 IGHV4-59*08             ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
st140vh                        ... ... ..c ctg tcc ctc acc tgc gct gtc tct ggt gac tcc ctc  
L10088 IGHV4-59*01             tcg gag ac- --- --- --- --- --- a-- --- --- --- -g- --- a--  
M29812 IGHV4-59*02             tcg gag ac- --- --- --- --- --- a-- --- --- --- -g- --- g--  
X56360 IGHV4-59*07             tcg gac ac- --- --- --- --- --- a-- --- --- --- -g- --- a--  
M95114 IGHV4-59*03             tcg gag ac- --- --- --- --- --- a-- --- --- --- -g- --- a--  
X87091 IGHV4-59*08             ... ... ... ... --- --- --- --- a-- --- --- --- -g- --- a--  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
st140vh                        ggt agt tac tac ... ... ... ... tgt acc tgg atc cga cag ccc  
L10088 IGHV4-59*01             a-- --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
M29812 IGHV4-59*02             a-- --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
X56360 IGHV4-59*07             a-- --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
M95114 IGHV4-59*03             a-- --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
X87091 IGHV4-59*08             a-n --- --- --- ... ... ... ... --g -g- --- --- --g --- ---  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
st140vh                        ccc ggg aag gga ctg gaa tgg gtg ggt tat atc tat tac agt ggg  
L10088 IGHV4-59*01             --a --- --- --- --- --g --- a-t --g --- --- --- --- --- ---  
M29812 IGHV4-59*02             --a --- --- --- --- --g --- a-t --g --- --- --- --- --- ---  
X56360 IGHV4-59*07             --a --- --- --- --- --g --- a-t --g --- --- --- --- --- ---  
M95114 IGHV4-59*03             --a --- --- --- --- --g --- a-t --g --- --- --- --- --- ---  
X87091 IGHV4-59*08             --a --- --- --- --- --g --- a-t --g --- --- --- --- --- ---  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
st140vh                        agc acc ... ... ... aat tat aac cct tcc ctc aag ... agt cga  
L10088 IGHV4-59*01             --- --- ... ... ... --c --c --- --c --- --- --- ... --- ---  
M29812 IGHV4-59*02             --- --- ... ... ... --c --c --- --c --- --- --- ... --- ---  
X56360 IGHV4-59*07             --- --- ... ... ... --c --c --- --c --- --- --- ... --- ---  
M95114 IGHV4-59*03             --- --- ... ... ... --c --c --- --c --- --- --- ... --- ---  
X87091 IGHV4-59*08             --- --- ... ... ... --c --c --- --c --- --- --- ... --- ---  
 
                               -------------------------------  FR3 - IMGT  --------------- 
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                                               80                  85                  90   
st140vh                        gcc gtc ata tca atc gac aca acc aac aac cgg ttc tcc ctg aac  
L10088 IGHV4-59*01             -t- ac- --- --- g-a --- --g t-- --g --- -a- --- --- --- --g  
M29812 IGHV4-59*02             -t- ac- --- --- g-a --- --g t-- --g --- -a- --- --- --- --g  
X56360 IGHV4-59*07             -t- ac- --- --- g-a --- --g t-- --g --- -a- --- --- --- --g  
M95114 IGHV4-59*03             -t- ac- --- --- g-a --- --g t-- --g --- -aa --- --- --- --g  
X87091 IGHV4-59*08             -t- ac- --- --- g-a --- --g t-- --g --- -a- --- --- --- --g  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
st140vh                        ctc agc tct gtg acc gct gga gac acg gcc gtg tat tat tgt gtg  
L10088 IGHV4-59*01             --g --- --- --- --- --- -cg --- --- --- --- --- --c --- -c-  
M29812 IGHV4-59*02             --g --- --- --- --- --- -cg --- --- --- --- --- --c --- -c-  
X56360 IGHV4-59*07             --g --- --- --- --- --- -cg --- --- --- --- --- --c --- -c-  
M95114 IGHV4-59*03             --g --- --- --- --- --- -cg --- --- --- --- --- --c --- -c- 
X87091 IGHV4-59*08             --g --- --- --- --- --c -c- --- n-- --- --- --- --c --- -c-  
 
                               _______  CDR3 -  IMGT _________ 
                                
st140vh                        aga gga aac ggc gcg ctc cta tcc tgg ggc caa gga acc ctg gt 
L10088 IGHV4-59*01             --- -a 
M29812 IGHV4-59*02             --- -a 
X56360 IGHV4-59*07             --- 
M95114 IGHV4-59*03              
X87091 IGHV4-59*08             --- 
 
St140vκ 
 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
st140vk                        ... ... ... ... ... cag tct cca tct tcc gtg tct gca tct gta  
V01577 IGKV1-12*01             gac atc cag atg acc --- --- --- --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             gac atc cag atg acc --- --- --- --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            gac atc cag atg acc --- --- --- --- --t --- --- --- --- ---  
K01323 IGKV1D-16*01            gac atc cag atg acc --- --- --- --c --a c-- --- --- --- ---  
V00558 IGKV1D-16*02            gac atc cag atg acc --- --- --- --c --a c-- --- --- --- ---  
 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
st140vk                        gga gac aga gtc acc atc act tgt cgg gcg agt cag ggt att agc  
V01577 IGKV1-12*01             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
K01323 IGKV1D-16*01            --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
V00558 IGKV1D-16*02            --- --- --- --- --- --- --- --- --- --- --g --- --- --- ---  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
st140vk                        agc tgg ... ... ... ... ... ... tta gcc tgg tat cag cag aaa  
V01577 IGKV1-12*01             --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
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K01323 IGKV1D-16*01            --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
V00558 IGKV1D-16*02            --- --- ... ... ... ... ... ... --- --- --- --- --- --- ---  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
st140vk                        cca ggg aaa gcc cct aag ctc ctg atc tat gct gca tcc ... ...  
V01577 IGKV1-12*01             --- --- --- --- --- --- --- --- --- --- --- --- --- ... ...  
V01576 IGKV1-12*02             --- --- --- --- --- --- --- --- --- --- --- --- --- ... ...  
X17263 IGKV1D-12*01            --- --- --- --- --- --- --- --- --- --- --- --- --- ... ...  
K01323 IGKV1D-16*01            --- -a- --- --- --- --- tc- --- --- --- --- --- --- ... ...  
V00558 IGKV1D-16*02            --- -a- --- --- --- --- tc- --- --- --- --- --- --- ... ...  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
st140vk                        ... ... ... ... ... agt ttg caa agt ggg gtc cca ... tca agg  
V01577 IGKV1-12*01             ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
V01576 IGKV1-12*02             ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
X17263 IGKV1D-12*01            ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
K01323 IGKV1D-16*01            ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
V00558 IGKV1D-16*02            ... ... ... ... ... --- --- --- --- --- --- --- ... --- ---  
 
                               -------------------------------  FR3 - IMGT  --------------- 
                                               80                  85                  90   
st140vk                        ttc agc ggc agt gga ... ... tct ggg aca gat ttc act ctc acc  
V01577 IGKV1-12*01             --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            --- --- --- --- --- ... ... --- --- --- --- --- --- --- --t  
K01323 IGKV1D-16*01            --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
V00558 IGKV1D-16*02            --- --- --- --- --- ... ... --- --- --- --- --- --- --- ---  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
st140vk                        atc agc agc ctg cag cct gaa gat ttt gca act tac tat tgt caa  
V01577 IGKV1-12*01             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
V01576 IGKV1-12*02             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
X17263 IGKV1D-12*01            --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
K01323 IGKV1D-16*01            --- --- --- --- --- --- --- --- --- --- --- --t --c --c ---  
V00558 IGKV1D-16*02            --- --- --- --- --- --- --- --- --- --- --- --t --c --c ---  
 
                               __________  CDR3 - IMGT  __________ 
                                
st140vk                        cag gct aac agt ttc cct cca agc acc ttc ggc caa ggg aca cg 
V01577 IGKV1-12*01             --- --- --- --- --- --- -- 
V01576 IGKV1-12*02             --- --- --- --- --- --- t- 
X17263 IGKV1D-12*01            --- --- --- --- --- --- -- 
K01323 IGKV1D-16*01            --- ta- --t --- -a- --- -- 
V00558 IGKV1D-16*02            --- ta- --t --- -a- --- -- 
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Scu68vh 
                              <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
scu68vh                        ... ... ... ... ... ... ..g ggg acc ... agg gtt cct tgg ccc  
M29811 IGHV4-61*01             cag gtg cag ctg cag gag tc- --c c-a ... g-a c-g gtg aa- --t  
X92230 IGHV4-61*03             cag gtg cag ctg cag gag tc- --c c-a ... g-a c-g gtg aa- --t  
AB019437 IGHV4-61*08           cag gtg cag ctg cag gag tc- --c c-a ... g-a c-g gtg aa- --t  
M29812 IGHV4-59*02             cag gtg cag ctg cag gag tc- --c c-a ... g-a c-g gtg aa- --t  
X56356 IGHV4-61*05             cag ctg cag ctg cag gag tc- --c c-a ... g-a c-g gtg aa- --t  
 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
scu68vh                        cgg gtg acc ctg tcc ctc acc tgc act gtc tct gga gtc tcc gtc  
M29811 IGHV4-61*01             tc- -a- --- --- --- --- --- --- --- --- --- --t -g- --- ---  
X92230 IGHV4-61*03             tc- -a- --- --- --- --- --- --- --- --- --- --t -g- --- ---  
AB019437 IGHV4-61*08           tc- -a- --- --- --- --- --- --- --- --- --- --t -g- --- ---  
M29812 IGHV4-59*02             tc- -a- --- --- --- --- --- --- --- --- --- --t -g- --- ---  
X56356 IGHV4-61*05             tc- -a- --- --- --- --- --- --- --- --- --- --t -g- --- a--  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
scu68vh                        gag gat gat act tat tat ... ... tgg acc tgg att cgc cag tcc  
M29811 IGHV4-61*01             agc ag- -g- -g- --c --c ... ... --- -g- --- --c --g --- c--  
X92230 IGHV4-61*03             agc ag- -g- -g- --c --c ... ... --- -g- --- --c --g --- c--  
AB019437 IGHV4-61*08           agc ag- -g- gg- --c --c ... ... --- -g- --- --c --g --- c--  
M29812 IGHV4-59*02             agt ag- t-c tac ... ... ... ... --- -g- --- --c --g --- c--  
X56356 IGHV4-61*05             agc ag- ag- -g- --c --c ... ... --- gg- --- --c --g --- c--  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
scu68vh                        cca ggg aag gga ctg gag tgg att ggc aat gtc tat tac agc ggg  
M29811 IGHV4-61*01             --- --- --- --- --- --- --- --- --g t-- a-- --- --- --t ---  
X92230 IGHV4-61*03             --- --- --- --- --- --- --- --- --g t-- a-- --- --- --t ---  
AB019437 IGHV4-61*08           --- --- --- --- --- --- --- --- --g t-- a-- --- --- --t ---  
M29812 IGHV4-59*02             --- --- --- --- --- --- --- --- --g t-- a-- --- --- --t ---  
X56356 IGHV4-61*05             --- --- --- --- --- --- --- --- --g t-- a-- --- --- --t ---  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
scu68vh                        aca aac ... ... ... tac tac aac ccc tcc ctc gag ... agt cga  
M29811 IGHV4-61*01             -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
X92230 IGHV4-61*03             -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
AB019437 IGHV4-61*08           -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
M29812 IGHV4-59*02             -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
X56356 IGHV4-61*05             -gc -c- ... ... ... a-- --- --- --- --- --- a-- ... --- ---  
 
                               -------------------------------  FR3 - IMGT  --------------- 
                                               80                  85                  90   
scu68vh                        gtc acc gtt tcg ctg gac acg tcc aac aat cag ttc tct ctg aaa  
M29811 IGHV4-61*01             --- --- a-a --a g-a --- --- --- --g --c --- --- --c --- --g  
X92230 IGHV4-61*03             --- --- a-a --a g-a --- --- --- --g --c --c --- --c --- --g  
AB019437 IGHV4-61*08           --- --- a-a --a g-a --- --- --- --g --c --- --- --c --- --g  
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M29812 IGHV4-59*02             --- --- a-a --a g-a --- --- --- --g --c --- --- --c --- --g  
X56356 IGHV4-61*05             --- --- a-a --a g-a --- -a- --- --g --c --- --- --c --- --g  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
scu68vh                        ctg agg tct gtg acc tct gcg gac acg gcc ata tat ttt tgt gtg  
M29811 IGHV4-61*01             --- --c --- --- --- g-- --- --- --- --- g-g --- -ac --- -c-  
X92230 IGHV4-61*03             --- --c --- --- --- g-- --- --- --- --- g-g --- -ac --- -c-  
AB019437 IGHV4-61*08           --- --c --- --- --- g-- --- --- --- --- g-g --- -ac --- -c-  
M29812 IGHV4-59*02             --- --c --- --- --- g-- --- --- --- --- g-g --- -ac --- -c-  
X56356 IGHV4-61*05             --- --c --- --- --- g-c --- --- --- --- g-g --- -ac --- -c-  
 
                               _______________________  CDR3 -  IMGT ______________________ 
                                
scu68vh                        aga gat gct tat tat gga ctg ggg tct ccc tca aac tgg ttt gac  
M29811 IGHV4-61*01             --- -- 
X92230 IGHV4-61*03             --- -- 
AB019437 IGHV4-61*08           --- -- 
M29812 IGHV4-59*02             --- -- 
X56356 IGHV4-61*05             --- 
 
                               ___ 
                                
scu68vh                        ccc tgg ggc caa gga ccc ctg gtc aca 
M29811 IGHV4-61*01              
X92230 IGHV4-61*03              
AB019437 IGHV4-61*08            
M29812 IGHV4-59*02              
X56356 IGHV4-61*05              
 
Scu68vl 
                               <---------------------------------------------  FR1 - IMGT   
                               1               5                   10                  15   
scu68vl                        tct tct gag ctg act cag gac cct gct ... gtg tct gtg gcc ttg  
X56178 IGLV3-19*01             --- --- --- --- --- --- --- --- --- ... --- --- --- --- ---  
Z73645 IGLV3-32*01             --c --- -g- -ca --- --- -tg --- --a ... --- --- --- --- ---  
X57826 IGLV3-1*01              --c -a- --- --- --- --- cca --c t-a ... --- --c --- t-- cca  
X97473 IGLV3-9*01              --c -a- --- --- --- --- cca -tc t-a ... --- --a --- --- c--  
D86994 IGLV3-27*01             --c -a- --- --- --a --- cca t-c t-a ... --- --a --- t-t cc-  
 
                               ------------------------------------------> ________________ 
                                               20                  25                  30   
scu68vl                        ggg cag aca gtc aca atc aca tgc cag gga gac agc ctc aaa agg  
X56178 IGLV3-19*01             --a --- --- --- -gg --- --- --- --a --- --- --- --- -g- --c  
Z73645 IGLV3-32*01             --a --a -tg -c- -gg --- --c --- --- --- --- --- a-g g-- g-c  
X57826 IGLV3-1*01              --a --- --- -c- -gc --- --c --- tct --- --t -aa t-g ggg gat  
X97473 IGLV3-9*01              --a --- --g -c- -gg --t --c --t gg- --- a-- -a- a-t gg- --t  
D86994 IGLV3-27*01             --a --- --- -c- -gg --- --c --- tca --- --t gta --g gc- -aa  
 
                               __  CDR1 - IMGT  ______________ <--------------------------  
                                               35                  40                  45   
scu68vl                        tat tat ... ... ... ... ... ... gca ggc tgg tat aag cag aag  
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X56178 IGLV3-19*01             --- --- ... ... ... ... ... ... --- a-- --- --c c-- --- ---  
Z73645 IGLV3-32*01             -c- --- ... ... ... ... ... ... -a- ca- --- --c c-- --- ---  
X57826 IGLV3-1*01              a-a --- ... ... ... ... ... ... --t t-- --- --- c-- --- ---  
X97473 IGLV3-9*01              a-a a-- ... ... ... ... ... ... -tg ca- --- --c c-- --- ---  
D86994 IGLV3-27*01             a-a --- ... ... ... ... ... ... --t c-g --- -tc c-- --- ---  
 
                                FR2 - IMGT  -------------------------> ______________  CDR2 
                                               50                  55                  60   
scu68vl                        cca gga cag gcc cct caa ctt gtc att tat gct aaa aac ... ...  
X56178 IGLV3-19*01             --- --- --- --- --- gt- --- --- --c --- -g- --- --- ... ...  
Z73645 IGLV3-32*01             --- --c --- --- --c gtg --g --- --c --- -a- -gc -gt ... ...  
X57826 IGLV3-1*01              --- --c --- t-- --- gtg --g --- --c --- caa g-t -g- ... ...  
X97473 IGLV3-9*01              --- --c --- --- --- gtg --g --- --c --- agg g-t -g- ... ...  
D86994 IGLV3-27*01             --- --c --- --- --- gtg --g --g --- --- aaa g-c -gt ... ...  
 
                                - IMGT  __________ <--------------------------------------- 
                                               65                  70                  75   
scu68vl                        ... ... ... ... ... agg cgg ccc tca ggg atc cca ... gac cga  
X56178 IGLV3-19*01             ... ... ... ... ... -ac --- --- --- --- --- --- ... --- ---  
Z73645 IGLV3-32*01             ... ... ... ... ... gac --- --- --- a-- --- --t ... --g ---  
X57826 IGLV3-1*01              ... ... ... ... ... -a- --- --- --- --- --- --t ... --g ---  
X97473 IGLV3-9*01              ... ... ... ... ... -ac --- --- --t --- --- --t ... --g ---  
D86994 IGLV3-27*01             ... ... ... ... ... ga- --- --- --- --- --- --t ... --g ---  
 
                               -------------------------------  FR3 - IMGT  --------------- 
                                               80                  85                  90   
scu68vl                        ttc tct ggg tcc aac ... ... tca gga gac aca gcc tcc ttg acc  
X56178 IGLV3-19*01             --- --- --c --- -g- ... ... --- --- a-- --- --t --- --- ---  
Z73645 IGLV3-32*01             --- --- --c --- --a ... ... --- --c a-- --- a-- a-- c-- ---  
X57826 IGLV3-1*01              --- --- --c --- --- ... ... --t --g a-- --- --- a-t c-- ---  
X97473 IGLV3-9*01              --- --- --c --- --- ... ... --g --g a-- --g --- a-- c-- ---  
D86994 IGLV3-27*01             --- --c --c --- -g- ... ... --- --g ac- --- -t- a-- --- ---  
 
                               ------------------------------------------------------> ____ 
                                               95                  100             104  
scu68vl                        atc act ggg gct cag gcg gaa gat gag gct gaa tat ttc tgt aat  
X56178 IGLV3-19*01             --- --- --- --- --- --- --- --- --- --- --c --- -a- --- --c  
Z73645 IGLV3-32*01             --- --- --- --c --- --t --g --- --- --- --t --- -a- -a- c-g  
X57826 IGLV3-1*01              --- -gc --- a-c --- --t atg --- --- --- --c --- -a- --- c-g  
X97473 IGLV3-9*01              --- -gc a-a --c --a --c -gg --- --- --- --c --- -a- --- c-g  
D86994 IGLV3-27*01             --- -gc --- --c --- -tt --g --- --- --- --c --- -a- --- t-c  
 
                               ______________  CDR3 - IMGT  ______________ 
                                
scu68vl                        tcc cgc gac ggc ttt gaa aat cat cgg gtg ctt ttc ggc gga ggc  
X56178 IGLV3-19*01             --- --g --- a-- ag- -gt --c --- -t 
Z73645 IGLV3-32*01             -tg ata --- aa- ca- -ct -c 
X57826 IGLV3-1*01              g-g t-g --- a-- agc act gca 
X97473 IGLV3-9*01              gtg t-g --- a-- agc act gca 
D86994 IGLV3-27*01             --t gcg -ct -a- aac a-t ct 
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scu68vl                        acc aag ctg acc gtc 
X56178 IGLV3-19*01              
Z73645 IGLV3-32*01              
X57826 IGLV3-1*01               
X97473 IGLV3-9*01               
D86994 IGLV3-27*01              
 112 
Acknowledgement 
 
I was very happy to be able to do translational research and I would like to express my sincere 
gratitude to Prof. Dr. M. Pfreundschuh for giving me the opportunity. I thank Dr. J. 
Voswinkel for his wonderful coaching, friendly advice and direct communication during the 
entire experimental period and writing period thereafter.  Also I thank Ms. G. Carbon for 
introducing me to laboratory techniques and the friendly support and advice during the entire 
period of experimentation. And I would like to give a big thanks to Ms. B. Bette for her help 
with the final ELISAs and for being a great colleague. 
 
Then I would like to thank all the people in the José Carreras Center for Immuno- and Gene 
Therapy of the department of Internal Medicine of University of the Saarland, Germany. You 
were wonderful colleagues and I really liked the friendly atmosphere in which I worked. I 
especially thank a number of persons who helped me with my research: Dr. G. Held and Dr. 
D. Preuss for help with phage library screening and Prof. Dr. K. Roemer and Kristina Heyne 
for their help with Western blots.  
 113 
Curriculum vitae 
 
Personal data: 
Name:     Augustijn Johannes Kerkdijk 
Date of birth;    23.12.1976 
Place of birth:    Purmerend, the Netherlands 
 
Education: 
1995     High School Diploma, Da Vinci College in Purmerend 
1995 – 1996 Study of Physics and Computer Science at University of 
Amsterdam 
1996 – 2002 Study for degree of Master of Science in Medicine 
2002 – 2004 Practical period of medical education, followed by 
medical registration in the Netherlands 
 
Work experience: 
2005 – 2006  Department of Internal Medicine of the Prison Hospital 
of the State of North Rhine-Westphalia, Germany 
 
2006 – 2007 M.D. studies at the University of the Saarland, Germany 
 
2007 - 2008 Department of Hematology and Oncology, University 
Medical School of the Saarland, Germany 
  
2008 -  Department of Diagnostic and Interventional Radiology, 
University of Leipzig, Germany 
 
 
 114 
Copyright information and notices  
 
Figure 1:  Derived from Uveitis.org, courtesy of Dr. Stephen Foster 
Figure 2:  Courtesy of Dr. A.R. Karim 
Figure 3:  Courtesy of Dr. A.R. Karim 
Figure 4:  With permission of Nature Publishing group and Elsevier ltd. 
Figure 5:  With permission from Dr. J. Voswinkel 
Figure 6:  With permission from Dr. J. Voswinkel 
Figure 7:  With permission from Dr. J. Voswinkel 
Figure 9:  With permission from Elsevier ltd. 
Figure 10:  With permission from Elsevier ltd. 
Figure 11:  With permission from Elsevier ltd. 
Figure 12:  With permission from Dr. G. Held 
Figure 13: With permission from Dr. G. Held 
Figure 14:  Permission granted to distribute this image by “G3pro”, from 
commons.wikimedia.org 
Figure 15: Permission granted to distribute this image by “madprime” from 
commons.wikimedia.org, image may be distributed freely 
Figure 16:  Public domain image from the federal government of the USA 
Figure 17: Permission granted to distribute this image by “Minestrone Soup”, from 
commons.wikimedia.org, image may be distributed freely 
Figure 18: With permission from Invitrogen (Karlsruhe, Germany) 
Figure 19: With permission from Invitrogen (Karlsruhe, Germany) 
Figure 20: Permission granted to distribute this image by “Dr d12”, from 
commons.wikimedia.org 
Figure 21: Permission granted to distribute this image by “Madprime”, from 
commons.wikimedia.org 
Figure 22: Permission granted to distribute this image by “Gluon”, from 
commons.wikimedia.org 
Figure 23: Permission granted to distribute this image by “Madprime”, from 
commons.wikimedia.org, image may be distributed freely 
Figure 24: Permission granted to distribute this image by Abizar Lakdawalla, from 
commons.wikimedia.org, image may be distributed freely 
Figure 26: With permission from Dr. G. Held 
Figure 27: With many thanks to Ms. S. Schaller 
 
The license to figures 15, 17, 23 and 24 is available under 
http://creativecommons.org/licenses/by-sa/2.5 
The license to figure 22 is available under http://creativecommons.org/licenses/by-sa/2.0/de/  
 
 
 115 
List of references 
 
 
 1.  Aries,P.M., Lamprecht,P. & Gross,W.L. Wegener's granulomatosis: a view from the 
granulomatous side of the disease. Isr. Med. Assoc. J. 7, 768-773 (2005). 
 2.  Bosch,X., Guilabert,A. & Font,J. Antineutrophil cytoplasmic antibodies. Lancet 368, 
404-418 (2006). 
 3.  Davis,J.A. et al. Determination of primary amino acid sequence and unique three-
dimensional structure of WGH1, a monoclonal human IgM antibody with anti-PR3 
specificity. Clin. Immunol. Immunopathol. 89, 35-43 (1998). 
 4.  de Haard,H.J. et al. A large non-immunized human Fab fragment phage library that 
permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 
274, 18218-18230 (1999). 
 5.  Drayton,D.L., Liao,S., Mounzer,R.H. & Ruddle,N.H. Lymphoid organ development: 
from ontogeny to neogenesis. Nat. Immunol. 7, 344-353 (2006). 
 6.  Falk,R.J., Terrell,R.S., Charles,L.A. & Jennette,J.C. Anti-neutrophil cytoplasmic 
autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. 
Proc. Natl. Acad. Sci. U. S. A 87, 4115-4119 (1990). 
 7.  Fink,L., Kwapiszewska,G., Wilhelm,J. & Bohle,R.M. Laser-microdissection for cell 
type- and compartment-specific analyses on genomic and proteomic level. Exp. Toxicol. 
Pathol. 57 Suppl 2, 25-29 (2006). 
 8.  Fujinaga,M., Chernaia,M.M., Halenbeck,R., Koths,K. & James,M.N. The crystal 
structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis 
antibodies. J. Mol. Biol. 261, 267-278 (1996). 
 9.  Hagen,E.C. et al. Diagnostic value of standardized assays for anti-neutrophil 
cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA 
Assay Standardization. Kidney Int. 53, 743-753 (1998). 
 10.  Hoffman,G.S. et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. 
Med. 116, 488-498 (1992). 
 11.  Invitrogen Corp. Zero Blunt TOPO PCR Cloning Kit manual. (2006). 
 12.  Jennette,J.C. et al. Nomenclature of systemic vasculitides. Proposal of an international 
consensus conference. Arthritis Rheum. 37, 187-192 (1994). 
 13.  Kallenberg,C.G., Heeringa,P. & Stegeman,C.A. Mechanisms of Disease: pathogenesis 
and treatment of ANCA-associated vasculitides. Nat. Clin. Pract. Rheumatol. 2, 661-
670 (2006). 
 14.  Kuppers,R., Zhao,M., Hansmann,M.L. & Rajewsky,K. Tracing B cell development in 
human germinal centres by molecular analysis of single cells picked from histological 
sections. EMBO J. 12, 4955-4967 (1993). 
 116 
 15.  Lamprecht,P. & Gross,W.L. Wegener's granulomatosis. Herz 29, 47-56 (2004). 
 16.  Lamprecht,P., Trabandt,A. & Gross,W.L. Clinical and immunological aspects of 
Wegener's granulomatosis (WG) and other syndromes resembling WG. Isr. Med. Assoc. 
J. 2, 621-626 (2000). 
 17.  Ludemann,J., Utecht,B. & Gross,W.L. Anti-neutrophil cytoplasm antibodies in 
Wegener's granulomatosis recognize an elastinolytic enzyme. J. Exp. Med. 171, 357-362 
(1990). 
 18.  Mahr,A.D., Neogi,T. & Merkel,P.A. Epidemiology of Wegener's granulomatosis: 
Lessons from descriptive studies and analyses of genetic and environmental risk 
determinants. Clin. Exp. Rheumatol. 24, S82-S91 (2006). 
 19.  Mullen,L.M., Nair,S.P., Ward,J.M., Rycroft,A.N. & Henderson,B. Phage display in the 
study of infectious diseases. Trends Microbiol. 14, 141-147 (2006). 
 20.  Muller,A. et al. Localized Wegener's granulomatosis: predominance of CD26 and IFN-
gamma expression. J. Pathol. 192, 113-120 (2000). 
 21.  Peen,E. & Williams,R.C., Jr. What you should know about PR3-ANCA. Structural 
aspects of antibodies to proteinase 3 (PR3). Arthritis Res. 2, 255-259 (2000). 
 22.  Popa,E.R., Stegeman,C.A., Kallenberg,C.G. & Tervaert,J.W. Staphylococcus aureus and 
Wegener's granulomatosis. Arthritis Res. 4, 77-79 (2002). 
 23.  Radford,D.J., Savage,C.O. & Nash,G.B. Treatment of rolling neutrophils with 
antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated 
adhesion. Arthritis Rheum. 43, 1337-1345 (2000). 
 24.  Rao,N.V. et al. Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. 
Structural and functional properties. J. Biol. Chem. 266, 9540-9548 (1991). 
 25.  Reinhold-Keller,E. et al. An interdisciplinary approach to the care of patients with 
Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 43, 
1021-1032 (2000). 
 26.  Sambrook, Fritsch & Maniatis. Molecular Cloning, a laboratory manual second edition.  
1-1-1989.  
 
 27.  Sarraf,P. & Sneller,M.C. Pathogenesis of Wegener's granulomatosis: current concepts. 
Expert. Rev. Mol. Med. 7, 1-19 (2005). 
 28.  Sibilia,J. et al. Structural analysis of human antibodies to proteinase 3 from patients with 
Wegener granulomatosis. J. Immunol. 159, 712-719 (1997). 
 29.  Stegeman,C.A., Tervaert,J.W., de Jong,P.E. & Kallenberg,C.G. Trimethoprim-
sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's 
granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med. 335, 
16-20 (1996). 
 117 
 30.  Stegeman,C.A. et al. Association of chronic nasal carriage of Staphylococcus aureus 
and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 120, 12-17 
(1994). 
 31.  Voswinkel,J. et al. Single cell analysis of B lymphocytes from Wegener's 
granulomatosis: B cell receptors display affinity maturation within the granulomatous 
lesions. Clin. Exp. Immunol. 154, 339-345 (2008). 
 32.  Voswinkel,J. et al. A novel system to test for specificity of B cell receptors from tissue 
of Wegener's granulomatosis patients. Clin. Exp. Rheumatol. 26, S90-S96 (2008). 
 33.  Voswinkel,J. et al. B lymphocyte maturation in Wegener's granulomatosis: a 
comparative analysis of VH genes from endonasal lesions. Ann. Rheum. Dis. 65, 859-
864 (2006). 
 34.  Watts,R.A., Lane,S. & Scott,D.G. What is known about the epidemiology of the 
vasculitides? Best. Pract. Res. Clin. Rheumatol. 19, 191-207 (2005). 
 35.  Xiao,H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase 
cause glomerulonephritis and vasculitis in mice. J. Clin. Invest 110, 955-963 (2002). 
 
 
